siRNAs, modifiers, conjugates, and their use to target and regulate FXI gene expression.

SiRNA sequences conjugated with GalNAc effectively target and suppress FXI gene expression, addressing the limitations of current anticoagulants by reducing bleeding risk and improving patient compliance through prolonged efficacy.

JP2026182852APending Publication Date: 2026-11-19BEIJING YUEKANGKECHUANG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026078945
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-13
Filing Date
2026-05-08
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current anticoagulants, such as vitamin K antagonists, heparin, and direct oral anticoagulants, inhibit both thrombus formation and hemostasis, increasing the risk of bleeding and requiring frequent administration, which affects patient compliance and is detrimental for patients with renal dysfunction.

Method used

Development of siRNA sequences targeting the FXI mRNA sequence, conjugated with N-acetylgalactosamine (GalNAc), to specifically suppress FXI gene expression, reducing the risk of bleeding while maintaining anticoagulant effects.

Benefits of technology

The siRNA conjugates significantly suppress FXI gene expression, providing a prolonged anticoagulant effect with reduced bleeding risk, demonstrated by high suppression rates in HepG2 cells, mice, and cynomolgus monkeys, lasting at least 49 to 84 days.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026182852000001
    Figure 2026182852000001
  • Figure 2026182852000002
    Figure 2026182852000002
  • Figure 2026182852000003
    Figure 2026182852000003
Patent Text Reader

Abstract

To provide an anticoagulant that can reduce the risk of bleeding and improve patient compliance. [Solution] This disclosure provides siRNAs, modifiers, conjugates, and uses thereof that target and regulate coagulation factor XI (FXI) gene expression. This disclosure involves designing a series of siRNAs based on the FXI messenger ribonucleic acid (mRNA) sequence, performing alternating modifications, and modifying using a set of specific modification templates. Cell and animal experiments have shown that oligonucleotide sequences modified with several alternating modifications and specific templates can significantly suppress FXI gene expression and are usable in the development of anticoagulants.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present disclosure belongs to the field of biopharmaceuticals, and specifically relates to siRNAs, modified products, conjugates that target and regulate FXI gene expression and uses thereof, for example, uses in regulating FXI gene expression or anticoagulation.

BACKGROUND ART

[0002] The coagulation cascade is jointly completed by the intrinsic coagulation pathway and the extrinsic coagulation pathway. Here, the intrinsic coagulation pathway includes coagulation factors FXI and FXII. In the classical model, after contact with collagen, RNA or polyphosphates, FXII is activated, FXIIa further activates downstream FXI to generate FXIa, and through downstream coagulation factors such as FIX and FX, thrombin is finally generated via the common pathway. Thrombin initiates fibrin formation and simultaneously activates FXI, forming positive feedback to amplify the coagulation process. Thrombosis is mainly caused by the intrinsic pathway.

[0003] The extrinsic coagulation pathway is generally triggered by Tissue Factor (TF), which activates FVII and further activates the common pathway, playing an important role in the hemostasis process. When vascular injury occurs, FVII or FVIIa in the blood binds to the extravascular-derived tissue factor TF, the FVIIa-TF complex converts FX to FXa, and then FXa converts a limited number of prothrombin molecules to thrombin. In the hemostasis process, FXI is converted to FXIa by thrombin, and subsequently FXIa causes clot consolidation via activation of FIX and its downstream pathway, but the overall effect is relatively small. Overall, FXI, an important molecule in the intrinsic coagulation pathway, plays a critical role in regulating the physiological process of thrombus formation, but is hardly involved in pathological processes such as hemorrhage that are mainly regulated by the extrinsic pathway, thus it can serve as a new target for antithrombotic therapy.

[0004] Among the currently available anticoagulants, vitamin K antagonists (VKA) mainly inhibit prothrombin and FX, while heparin and direct oral anticoagulants (DOAC) mainly inhibit FXa and thrombin. All of these multiple drugs can inhibit thrombus formation and may also inhibit the hemostatic function related to the extrinsic coagulation pathway, thus carrying a certain risk of bleeding during the treatment process. In contrast, FXI, the target in the present study, has an extremely minor role in the hemostasis process but plays an essential role in the thrombus formation process, which can effectively separate the processes of hemostasis and thrombus formation, and therefore can reduce the bleeding risk while exerting an anticoagulant effect. In addition, the fully modified siRNA drug conjugated with GalNAc has good durability, can achieve administration once every six months, has a sustained therapeutic effect, and significantly improves patient compliance. Summary of the Invention Problems to be Solved by the Invention

[0005] Among the anticoagulants commonly used in current clinical practice, vitamin K antagonists mainly inhibit prothrombin and FX, while heparin and direct oral anticoagulants (DOAC) mainly inhibit FXa and thrombin. All of these multiple drugs can inhibit thrombus formation and may also inhibit the hemostatic function related to the extrinsic coagulation pathway, thus carrying a certain risk of bleeding during the treatment process. In addition, many anticoagulant small-molecule inhibitors under development require daily administration, resulting in low patient compliance. Furthermore, for patients with renal dysfunction, drugs metabolized by the kidneys have a significant impact on renal function. Therefore, there is an urgent need for research and development of anticoagulants that can reduce the bleeding risk and improve patient compliance. Means for Solving the Problems

[0006] The present disclosure designs a series of siRNA sequences targeting the FXI mRNA sequence, and performs specific template modification to conjugate N-acetylgalactosamine (GalNAc).

[0007] This disclosure screens several alternating modifications and specific modification sequences that exhibit a significant repressive effect on FXI gene expression by modifying a designed siRNA sequence.

[0008] In one embodiment, the present disclosure provides an siRNA double-stranded oligonucleotide double-stranded comprising a sense strand paired with an antisense strand.

[0009] In another embodiment, the present disclosure provides a conjugate for reducing FXI expression, comprising the siRNA double strand and a conjugate group ligated thereto.

[0010] In another embodiment, the present disclosure provides a nucleic acid protein composition comprising the double-stranded region of the siRNA double-stranded region or the antisense strand of the double-stranded region, and a nuclease.

[0011] In another embodiment, the present disclosure provides a recombinant vector comprising a nucleic acid molecule encoding the siRNA double strand described above.

[0012] In some embodiments, the vector skeleton of the recombinant vector is selected from recombinant viroid-derived circular RNA vectors, tRNAs, rRNA scaffolds, and chimeric tRNA / pre-mi RNA vectors.

[0013] In another embodiment, the present disclosure provides recombinant cells that synthesize and secrete the above-mentioned siRNA double strands.

[0014] In some embodiments, the recombinant cells are selected from Rhodopseudomonas sulfidophila and ribonuclease III-deficient Corynebacterium glutamicum.

[0015] In another aspect, the present disclosure provides a method for preparing siRNA double strands, the method comprising culturing or chemically synthesizing the recombinant cells.

[0016] In another embodiment, the present disclosure provides a pharmaceutical composition comprising the siRNA double strand, the conjugate, or the nucleic acid protein composition, and a pharmaceutically acceptable carrier.

[0017] In another embodiment, the Disclosure provides a method for suppressing FXI gene expression, the method comprising contacting target cells with the siRNA double strand, the conjugate, the nucleic acid protein composition, or the pharmaceutical composition.

[0018] In some embodiments, the method is for non-diagnostic or non-therapeutic purposes.

[0019] In some embodiments, the method is performed in vivo or in vitro.

[0020] In another aspect, the disclosure provides the use of the siRNA double strand, the conjugate, the nucleic acid protein composition, or the pharmaceutical composition in the manufacture of a drug for treating a disease associated with FXI gene expression.

[0021] The aforementioned FXI gene expression-related diseases are selected from diseases resulting from overexpression of the FXI protein, pathogenic mutations of the FXI gene, metabolic abnormalities of the FXI protein, or abnormal interactions between FXI and other substances.

[0022] In some embodiments, the FXI gene expression-related disease is selected from thrombotic diseases, including deep vein thrombosis, venous or arterial thrombosis, ischemic stroke, pulmonary embolism, myocardial infarction, stroke, Alzheimer's disease, chronic kidney disease, or thrombosis associated with end-stage renal failure.

[0023] In another aspect, the disclosure provides the use of the siRNA double strands, the conjugates, the nucleic acid protein compositions, or the pharmaceutical compositions for the treatment of diseases associated with FXI gene expression, such as stroke prevention in atrial fibrillation, end-stage renal failure dialysis, and anticoagulation in knee replacement surgery.

[0024] In another embodiment, the present disclosure provides a method for treating a disease related to FXI gene expression, the method comprising administering an effective amount of the siRNA double strand, the conjugate, the nucleic acid protein composition, or the pharmaceutical composition to a subject in need thereof.

[0025] In another aspect, the disclosure provides the use of the siRNA double strand, the conjugate, the nucleic acid protein composition, or the pharmaceutical composition in the manufacture of a drug for treating cardiovascular disorders.

[0026] In another aspect, the present disclosure provides the use of the siRNA double strands, the conjugates, the nucleic acid protein compositions, or the pharmaceutical compositions for the treatment of cardiovascular disorders.

[0027] In another embodiment, the present disclosure provides a method for treating cardiovascular disorders, the method comprising administering an effective amount of the siRNA double strand, the conjugate, the nucleic acid protein composition, or the pharmaceutical composition to a subject in need thereof.

[0028] Effects of the invention: The beneficial effects obtained from this disclosure are at least as follows:

[0029] (1) Sequences using fluorine-oxygen alternating modification and template modifications disclosed herein can significantly suppress the expression level of the target gene FXI in HepG2 cells. The suppression rate is significantly higher than that of the highly active sequences in the disclosed patent.

[0030] (2) The siRNA conjugate coupled with the GalNAc conjugate group G101 of this disclosure showed a high suppression rate of target gene FXI expression in mouse in vivo experiments, and the duration was at least 49 days.

[0031] (3) The siRNA conjugate coupled with the GalNAc conjugate group G101 of this disclosure exhibits a high inhibitory effect on the expression level and activity of the target gene FXI, and a prolongation effect on APTT (activated partial thromboplastin time), with a duration of at least 84 days, in cynomolgus monkey in vivo experiments.

[0032] (4) Several basic sequences show high suppression rates against gene FXI when multiple modification templates are used. [Modes for carrying out the invention]

[0033] To make this disclosure easier to understand, we will first define some terms. Note that when a range of a single value or parameter is listed, the intermediate values ​​and ranges of these reference values ​​are also intended to be part of this disclosure.

[0034] As used herein, the articles “one” and “one kind” ("a" and "an") refer to one or more than one (i.e., at least one) grammatical object of the article. For example, “one element” refers to one or more than one element, e.g., multiple elements.

[0035] The term "including," when used here, refers to the phrase "including, but not limited to," and is used interchangeably with other terms.

[0036] The term "or," unless otherwise explicitly indicated by the context, refers to and is used interchangeably with the term "and / or" when used here.

[0037] As used herein, the terms “approximate” or “approximate,” applied to one or more target values, refer to a value similar to the reference value. In some embodiments, unless otherwise specified or the context makes it clear that, the terms “approximate” or “approximate” refer to a value within the range of 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less, in either direction (larger or smaller) of the reference value (except where such a number exceeds 100% of the possible value).

[0038] As used herein, "FXI" refers to the coding gene for coagulation factor XI or the protein expressed by said gene.

[0039] The term "FXI gene" can refer to the wild-type FXI gene or an FXI gene variant with sequence mutations. Many sequence mutations in the FXI gene have been identified and can be found, for example, in NCBIdbSNP and UniProt (see, for example, ncbi.nlm.nih.gov / snp).

[0040] "G," "C," "A," and "U" typically represent nucleotides containing guanine, cytosine, adenine, and uracil as bases, respectively. "T" and "dT" are used interchangeably here and refer to deoxyribonucleotides whose nucleic acid base is thymine, e.g., deoxyribothymine, 2'-deoxythymidine, or thymidine. However, it should be understood that the terms "ribonucleotide," "nucleotide," or "deoxyribonucleotide" may further refer to modified nucleotides (as will be further detailed below) or alternative substitutions. Those skilled in the art should be well aware that guanine, cytosine, adenine, and uracil can be substituted with other parts without substantially altering the base-pairing properties of oligonucleotides (including nucleotides having such substitutions). For example, a nucleotide containing inosine as its base can pair with a nucleotide containing adenine, cytosine, or uracil, but is not limited to these pairings. Therefore, nucleotides containing uracil, guanine, or adenine may be substituted in the nucleotide sequences of this disclosure with, for example, nucleotides containing inosine. Sequences containing such substitutions are applicable to, but are not limited to, double-stranded ribonucleic acid, double-stranded ribonucleic acid modifiers, double-stranded ribonucleic acid conjugates, pharmaceutical compositions and methods of this disclosure.

[0041] The terms “complementary,” “fully complementary,” and “substantially complementary” are used herein to refer to base pairing between the sense and antisense strands of an siRNA, or between the antisense strand of an siRNA and a target sequence, and can be understood from the context in which they are used. In some forms herein, a first nucleotide sequence and a second nucleotide sequence listing are considered complementary if they exhibit sequence complementarity of at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%. In one exemplary embodiment, 18 of the 20 nucleic acid bases of the first nucleotide sequence pair with the corresponding region of the second nucleotide sequence, achieving 90% complementarity. The terms "double-stranded ribonucleic acid," "double-stranded RNA (dsRNA) molecule," "dsRNA," and "double-stranded ribonucleic acid" are used interchangeably and specifically refer to a complex of ribonucleic acid molecules that have a double-stranded structure and contain two antiparallel, complementary or substantially complementary nucleic acid strands with "sense" and "antisense" orientations relative to a target gene, such as the FXI gene. In some examples, double-stranded ribonucleic acid (dsRNA) triggers the degradation of target RNA, such as mRNA, through a post-transcriptional gene silencing mechanism (referred to here as RNA interference or RNAi).

[0042] In this specification, in some cases, “siRNA double-stranded” and “double-stranded RNAi agent” also typically refer to the technical meanings indicated by the above definitions. As is well known in the art, the terms “siRNA double-stranded,” “double-stranded RNAi agent,” “RNAi agent,” “small interfering ribonucleic acid,” or “siRNA” refer to small interfering ribonucleic acid RNAi molecules. These are double-stranded RNA molecules, also called short interfering RNA or silencing RNA in the art. siRNA generally consists of a sense strand (also called a passenger strand) and an antisense strand (also called a guide strand), where each strand is 17 to 30 nucleotides long, and generally 19 to 25 nucleotides long, where the antisense strand is complementary to the target nucleic acid (appropriately a mature mRNA sequence) (e.g., at least 95% complementary, e.g., perfectly complementary), and the sense strand and antisense strand are complementary so that they form a double-stranded or double-stranded region. The sense and antisense strands of siRNA can form blunt-ended double hedges or 3' overhang (also called overhang ends) double hedges, for example, with a length of one, two, or three nucleotides, similar to the product produced by Dicer, and capable of forming a RISC substrate in the body. Effective extended forms of the Dicer substrate are described in US8349809 and US8513207, which are incorporated herein by reference. In some examples, both the sense and antisense strands have 3' overhangs with a length of two nucleotides. Thus, the length of the double-stranded region may be, for example, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides, for example, with a length of 19, 20, 21, 22, or 23 nucleotides.

[0043] In this specification, “siRNA” also refers in some cases to “basic sequence.” In this specification, “basic sequence” specifically refers in some cases to an siRNA double strand in which each nucleotide in the double-stranded ribonucleic acid is an unmodified nucleotide, and also appears throughout the specification as “motif,” “siRNA motif,” etc. Therefore, in this specification, “siRNA,” “basic sequence,” “motif,” and “siRNA motif” are used interchangeably, and their meanings include the corresponding nucleotide sequence order of the siRNA double strand they refer to. In this specification, those skilled in the art will be able to clearly understand the precise technical meanings they refer to from the technical meaning of the context. The 5' terminal nucleotide of the antisense strand of the motif may or may not be linked to a 5' phosphate group or a 5' phosphate derivative.

[0044] In this specification, "siRNA modifier" refers to a double-stranded ribonucleic acid containing at least one modified nucleotide, and in some cases also appears as "double-stranded ribonucleic acid modifier." In this specification, the relevant siRNA modifiers were prepared by modifying an siRNA motif with different modification forms. For example, in some embodiments, alternatingly modified siRNA modifiers are obtained by modifying the motif using alternating modification forms. In some other embodiments, siRNA modifiers modified with a specific modification template are obtained by modifying the motif using a modification form of a specific modification template. Also in some embodiments, off-target-preventing modified siRNA modifiers are obtained by modifying the motif using the off-target-preventing modification forms described herein. In some cases, the relevant siRNA modifier having multiple modification forms can be obtained by simultaneously modifying the same siRNA motif using multiple different modification forms.

[0045] In this specification, "siRNA conjugate" refers to a double-stranded ribonucleic acid conjugate or a conjugate of a double-stranded ribonucleic acid modifier obtained by linking a conjugate group to a double-stranded ribonucleic acid or a double-stranded ribonucleic acid modifier. Preferably, "siRNA conjugate" refers to a conjugate of a double-stranded ribonucleic acid modifier.

[0046] In some cases of this specification, "siRNA" may refer not only to the unmodified siRNA double strands (also called siRNA motifs) described above, but also to corresponding siRNA modifiers and / or siRNA conjugates. In contexts including, but not limited to, therapeutic methods and therapeutic agents, siRNA comprehensively refers to at least one of siRNA motifs, siRNA modifiers, and / or siRNA conjugates. Those skilled in the art will be able to clearly understand the specific technical meaning from the context.

[0047] The term “antisense strand” refers to a strand of double-stranded ribonucleic acid (e.g., double-stranded RNA as used herein) that contains a region substantially complementary to the target sequence. As used herein, the term “complementary region” refers to a region on the antisense strand that is substantially complementary to the sequence as defined herein (e.g., the target sequence). If the complementary region is not perfectly complementary to the target sequence, the mismatch may be located within the molecule or in the terminal region. Typically, the most acceptable mismatches occur in the terminal region, e.g., within 5, 4, 3, 2, or 1 nucleotides at the 5' and / or 3' ends.

[0048] As used herein, the term "sense strand" refers to a strand of double-stranded ribonucleic acid that contains a region substantially complementary to the antisense strand (as defined herein).

[0049] The term "alternating modification" refers to a modification method in which 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F) modifications are applied to nucleotides according to the nucleotide sequence order of double-stranded ribonucleic acid. For example, in the antisense strand of siRNA, odd-numbered positions (i.e., positions 1, 3, 5, 7, 11, 13, 15, 17, 19, 21, and 23) are modified with 2'-methoxy, and even-numbered positions (i.e., positions 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22) are modified with 2'-fluoro. For the sense strand complementary to the antisense strand, the positions on the sense strand corresponding to the 2'-methoxy modifications on the antisense strand are modified with 2'-fluoro, and 2'-methoxy modifications are applied at complementary pairing positions on the sense strand where 2'-fluoro modifications are used on the antisense strand.

[0050] In RNA interference (RNAi), target gene repression is achieved by the AGO2 protein loading the antisense strand of siRNA to form a silencing complex (RISC), after which the gene's transcript mRNA is cleaved. Loading the RISC requires phosphorylation (5'-phosphate) of the 5' end of the antisense strand. 5'-terminal phosphorylation may occur spontaneously within the cell by cleavage and polyadenylation factor I subunit 1 (Clp1), or it may be achieved chemically. The term "spontaneous 5'-terminal phosphorylation" or "simple, direct 5'-terminal phosphorylation" refers to the 5'-terminal phosphorylation of the siRNA antisense strand being completed in the intracellular environment and not through chemical synthesis.

[0051] In this specification, “conjugate group” refers to a GalNAc derivative attached to an oligonucleotide. In some cases, the conjugate group includes a targeting group (also called a ligand) and optionally further includes a linker, such as a GalNAc derivative linked to an oligonucleotide via a branched linker arm of divalent, trivalent, or tetravalent valencies, respectively, or a GalNAc derivative attached to an oligonucleotide via a monovalent linker arm. In many cases, both “ligand” and “conjugate group” have meanings well known in the art.

[0052] As used herein, the term “suppression” is interchangeable with “reduction,” “silencing,” “downregulation,” “deterrence,” and other similar terms, and includes any level of suppression. In some cases herein, “regulation” refers to “suppression,” and those skilled in the art will be able to clearly understand its specific meaning from the context.

[0053] As used herein, the phrase “suppress FXI expression” includes suppressing the expression of any FXI gene (e.g., mouse FXI gene, rat FXI gene, monkey FXI gene, or human FXI gene) and variants of the FXI gene (e.g., naturally occurring variants) or mutants. Thus, the FXI gene may be a wild-type FXI gene, a mutant FXI gene, or a genetically engineered cell, cell population, or transgenic FXI gene in the context of an organism.

[0054] "Suppressing FXI gene expression" includes any level of suppression of the FXI gene, for example, at least partially suppressing the expression of the FXI gene, for example, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0055] FXI gene expression can be assessed based on the levels of any variable related to FXI gene expression, such as FXI mRNA levels or FXI protein levels. Repression of FXI gene expression can be assessed by a decrease in the absolute or relative levels of one or more of these variables compared to control levels. The control level may be any type of control level used in this art, such as a baseline level before administration, or a level determined from similarly untreated or controlled subjects, cells, or samples (e.g., a buffer-only control or an inactivator control).

[0056] In this specification, in some cases, the meaning of "regulation" may be the same as "suppression," and accordingly, "regulating LPA gene expression" may mean "suppressing LPA gene expression." Those skilled in the art will be able to clearly understand the specific technical meaning from the context.

[0057] As used herein, “patient” or “subject” is intended to include human or non-human animals, preferably mammals, such as monkeys. More preferably, the subject or patient is human.

[0058] As used herein, “FXI-related disease” is intended to include any disease associated with the FXI gene or protein. Such diseases may be caused, for example, by overproduction of the FXI protein, mutations in the FXI gene, abnormal cleavage of the FXI protein, or abnormal interactions between FXI and other proteins or other endogenous or exogenous substances. Exemplary FXI-related diseases include thrombotic diseases, including deep vein thrombosis, venous or arterial thrombosis, ischemic stroke, pulmonary embolism, myocardial infarction, stroke, Alzheimer's disease, chronic kidney disease, or end-stage renal failure.

[0059] As used herein, “therapeutic dose” is intended to include an amount of RNAi agent sufficient to achieve treatment of an FXI-associated disease (e.g., by reducing, improving, or maintaining the symptoms of the pre-existing disease or one or more diseases) when administered to a patient for the treatment of the disease. The “therapeutic dose” may vary depending on the RNAi agent, the method of administration of the reagent, the disease and its severity, and the patient’s medical history, age, weight, family history, genetic makeup, stage of the pathological process mediated by FXI expression, type of previous or combination therapy (if any), and other individual characteristics of the patient to be treated.

[0060] As used herein, “Prophylactic effective dose” refers to an amount of RNAi agent sufficient to prevent or improve FXI-related disease or one or more symptoms of the disease when administered to a subject who has not yet experienced or shown symptoms of FXI-related disease but is potentially susceptible to the disease. Improvement of disease includes slowing the progression of the disease or reducing the severity of the disease if it develops later. The “Prophylactic effective dose” may vary depending on the RNAi agent, the method of administration of the reagent, the degree of risk of the disease, and the patient’s medical history, age, weight, family history, genetic makeup, type of previous or combination therapy (if any), and other individual characteristics of the patient being treated.

[0061] The “therapeutic effective dose” or “preventive effective dose” further includes the amount of RNAi agent that produces a desired local or systemic effect under a reasonable benefit / risk ratio applicable to any treatment. The RNAi agent used in the method of the present disclosure may be administered in an amount sufficient to produce a reasonable benefit / risk ratio applicable to such treatment.

[0062] As used herein, the term “sample” includes similar fluids, cells, or tissues isolated from a subject, as well as collections of fluids, cells, or tissues present within the body of the subject. Examples of biological fluids include blood, serum and serosal fluid, plasma, cerebrospinal fluid, ocular fluid, lymph, urine, saliva, and the like. Tissue samples may include samples from tissue, organs, or local areas. For example, a sample may originate from a specific organ, a part of an organ, or fluids or cells within those organs. In some embodiments, a sample may originate from the liver (e.g., the whole liver or some parts of the liver, or some type of cells within the liver, e.g., hepatocytes). In preferred embodiments, “sample derived from subject” refers to blood or plasma taken from the subject. In other embodiments, “sample derived from subject” refers to liver tissue (or its subcomponents) derived from the subject.

[0063] In this specification, unless otherwise specified, any reference to any nucleotide position on any strand, such as an siRNA motif, siRNA modifier, siRNA conjugate, or siRNA double strand, means the 5' to 3' direction.

[0064] In one embodiment, the Disclosure provides an siRNA double-stranded nucleotide for targeting and regulating FXI gene expression, comprising a sense strand and an antisense strand forming a reverse complementary double-stranded region, wherein the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to a target sequence whose nucleotide sequence is TTTCAGGATGATTTTCTTATATCAAGT (SEQ ID NO: 773) or ACTTCAGTTTCTGGTGAATGT (SEQ ID NO: 774).

[0065] The above target sequence is derived from Homo sapiens coagulation factor XI (F11), transcript variant 1, with accession number NM_000128.4 in the NCBI database.

[0066] In some embodiments, the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof in the sequence shown in any one of SEQ ID NO: 114-118, 121-123, and 139.

[0067] In some embodiments, the length of the inversely complementary double-stranded region is 17–21 bp, for example, 20 or 21 bp.

[0068] In some embodiments, the sense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof in the sequence shown in any one of SEQ ID NO: 8-12, 15-17, and 33.

[0069] In some embodiments, the sense strand and the antisense strand each independently contain 19 to 23 nucleotides, preferably the sense strand contains 19 to 21 nucleotides and the antisense strand contains 21 to 23 nucleotides.

[0070] In some embodiments, the siRNA duplex comprises one or at least two combinations selected from oligonucleotide duplexes consisting of the following sense strand-antisense strand pairings, wherein the sense strand and antisense strand each independently comprises at least one modified nucleotide. (1) The sense strand has the sequence shown in SEQ ID NO:8 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:114 or a fragment thereof. (2) The sense strand has the sequence shown in SEQ ID NO:9 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:115 or a fragment thereof. (3) The sense strand has the sequence shown in SEQ ID NO:10 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:116 or a fragment thereof. (4) The sense strand has the sequence shown in SEQ ID NO:11 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:117 or a fragment thereof. (5) The sense strand has the sequence shown in SEQ ID NO:12 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:118 or a fragment thereof. (6) The sense strand has the sequence shown in SEQ ID NO:15 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:121 or a fragment thereof. (7) The sense strand has the sequence or fragment thereof shown in SEQ ID NO:16, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:122. (8) The sense strand has the sequence shown in SEQ ID NO:17 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:123 or a fragment thereof. (9) The sense strand has the sequence shown in SEQ ID NO:33 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO:139 or a fragment thereof.

[0071] In some embodiments, siRNA double-stranded cells are RNAi agents for suppressing FXI gene expression.

[0072] In some embodiments, the difference between the sense strand and any one of the sequences among SEQ ID NO: 8-12, 15-17, and 33 is 1-3 nucleotides.

[0073] In some embodiments, the difference between the antisense strand and any one of the sequences among SEQ ID NO: 114-118, 121-123, and 139 is 1 to 3 nucleotides.

[0074] In some embodiments, the number of nucleotides in the sense strand and the number of nucleotides in the antisense strand are the same or different.

[0075] In some embodiments, the sense strand has 19 nucleotides, and the antisense strand has 19 nucleotides.

[0076] In some embodiments, the sense strand has 19 nucleotides, and the antisense strand has 21 nucleotides.

[0077] In some embodiments, the sense strand has 20 nucleotides, and the antisense strand has 20 nucleotides.

[0078] In some embodiments, the sense strand has 20 nucleotides, and the antisense strand has 22 nucleotides.

[0079] In some embodiments, the sense strand has 21 nucleotides, and the antisense strand has 21 nucleotides.

[0080] In some embodiments, the sense strand has 21 nucleotides, and the antisense strand has 23 nucleotides.

[0081] In some embodiments, the sense strand has 23 nucleotides, and the antisense strand has 23 nucleotides.

[0082] In some embodiments, the sense strand and the antisense strand each independently contain at least one modified nucleotide.

[0083] In some embodiments, at least one modified nucleotide is one or at least two selected from the group consisting of deoxy-nucleotides, 3'-terminal deoxythymine (dT) nucleotides, 2'-O-methyl-modified nucleotides, 2'-fluoro-modified nucleotides, 2'-deoxy-modified nucleotides, lock nucleotides, unlock nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, non-basic nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-hydroxy-modified nucleotides, 2'-methoxyethyl-modified nucleotides, 2'-O-alkyl-modified nucleotides, morpholinyl nucleotides, phosphoramides, nucleotides containing non-natural bases, tetrahydropyran-modified nucleotides, 1,5-anhydrohexitol-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing a phosphorothioate group, nucleotides containing a methyl phosphate group, nucleotides containing a 5'-phosphate, and nucleotides containing a 5'-phosphate mimetic.

[0084] In some embodiments, at least one strand contains the 3' overhang of at least one nucleotide.

[0085] In some embodiments, at least one strand contains the 3' overhanging ends of at least two nucleotides.

[0086] In some embodiments, the length of the double-stranded region of the siRNA double-strand is 15 to 30 pairs of nucleotides.

[0087] In some embodiments, the length of the double-stranded region of the siRNA double-strand is 17 to 25 pairs of nucleotides.

[0088] In some embodiments, the length of the double-stranded region of the siRNA double-strand is 19 to 23 pairs of nucleotides.

[0089] In some embodiments, the length of the double-stranded region of the siRNA double-strand is 21 pairs of nucleotides.

[0090] In some embodiments, each chain has 15 to 30 nucleotides.

[0091] In some embodiments, each chain has 19 to 25 nucleotides.

[0092] In some embodiments, the modification of all nucleotides in the sense and antisense strands is a modification at the 2' position of the nucleotide ribose.

[0093] In some embodiments, the modification at the 2' position of the nucleotide ribose is one or a combination of any of the following selected from 2'-methoxy modification, 2'-methoxyethyl modification, 2'-fluoro modification, 2'-benzyloxy modification, 2'-methylcarbonylamino modification, and 2'-pyridylmethoxy modification.

[0094] In some embodiments, the modification at the 2' position of each nucleotide ribose is selected from a combination of 2'-methoxy modification and 2'-fluoro modification.

[0095] In some embodiments, the modification at the 2' position of each nucleotide ribose is selected from an alternating combination of 2'-methoxy and 2'-fluoro modifications.

[0096] In some embodiments, the chemical modification of the 2' position of each nucleotide ribose is such that all odd-numbered positions on the antisense strand are 2'-methoxy modified, all even-numbered positions are 2'-fluoro modified, and on the sense strand, the position opposite the 2'-methoxy modification on the antisense strand is 2'-fluoro modified, and the position opposite the 2'-fluoro modification is 2'-methoxy modified.

[0097] In some embodiments, when the sense strand has an odd number of nucleotides, the modification configuration of the 2' position of each nucleotide ribose is such that all odd positions of the sense strand are 2'-fluoromodified and all even positions are 2'-methoxymodified, and all odd positions of the antisense strand are 2'-methoxymodified and all even positions are 2'-fluoromodified.

[0098] In some embodiments, when the sense strand has an even number of nucleotides, the modification configuration of the 2' position of each nucleotide ribose is such that all odd positions of the sense strand are 2'-methoxy modified and all even positions are 2'-fluoro modified, and all odd positions of the antisense strand are 2'-methoxy modified and all even positions are 2'-fluoro modified.

[0099] In some embodiments, nucleotides are linked to each other by 3',5'-phosphodiester bonds.

[0100] In some embodiments, nucleotides are linked to each other by 3',5'-phosphorothioate bonds.

[0101] In some embodiments, the nucleotides between the 1st and 2nd positions of the 3' and / or 5' ends of the sense and / or antisense strand of the siRNA modifier are 3',5'-phosphorothioate bonds, for example, in some embodiments, forming chirally pure 3',5'-phosphorothioate bonds. In some embodiments, there may be one, two, or three 3',5'-phosphorothioate bonds between the nucleotides between the 1st and 4th positions from the 5' end of the sense and / or antisense strand, and there may be one, two, or three 3',5'-phosphorothioate bonds between the nucleotides between the 1st and 4th positions from the 3' end of the antisense strand.

[0102] In some embodiments, the sense strand has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between the nucleotides at positions 2 and 3 from its 5' end, the antisense strand also has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between the nucleotides at positions 2 and 3 from its 5' end, and the antisense strand also has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between the nucleotides at positions 2 and 3 from its 3' end. In some specific embodiments, the sense strand and / or the antisense strand have alternating fluorine-oxygen modifications.

[0103] In some embodiments, the siRNA duplex comprises one or at least two combinations selected from the following oligonucleotide duplexes consisting of sense strand-antisense strand pairings: (1) The sense strand has the sequence shown in SEQ ID NO:220, and the antisense strand has the sequence shown in SEQ ID NO:326. (2) The sense strand has the sequence shown in SEQ ID NO:221, and the antisense strand has the sequence shown in SEQ ID NO:327. (3) The sense strand has the sequence shown in SEQ ID NO:222, and the antisense strand has the sequence shown in SEQ ID NO:328. (4) The sense strand has the sequence shown in SEQ ID NO:223, and the antisense strand has the sequence shown in SEQ ID NO:329. (5) The sense strand has the sequence shown in SEQ ID NO:224, and the antisense strand has the sequence shown in SEQ ID NO:330. (6) The sense strand has the sequence shown in SEQ ID NO:227, and the antisense strand has the sequence shown in SEQ ID NO:333. (7) The sense strand has the sequence shown in SEQ ID NO:228, and the antisense strand has the sequence shown in SEQ ID NO:334. (8) The sense strand has the sequence shown in SEQ ID NO:229, and the antisense strand has the sequence shown in SEQ ID NO:335. (9) The sense strand has the sequence shown in SEQ ID NO:245, and the antisense strand has the sequence shown in SEQ ID NO:351.

[0104] In some embodiments, the oligonucleotide has alternating fluorine-oxygen modification or template modification.

[0105] In some embodiments, phosphorylation of the 5'-position carbon atom of the 5'-terminal nucleotide glycoside of the modified antisense chain includes, but is not limited to, 5'-position phosphorylation groups such as 5'-vinylphosphonate (5'-E-VP), 5'-methylphosphonate (5'-MP), 5'-C-methylphosphate, 5'-phosphorothioate (5'-PS), and 5'-phosphate (5'-P). The structure of the modified nucleotide is as follows: [ka] Here, R is hydrogen, hydroxyl group, amino group, C 1-4 Alkyl group, aromatic group, C 1-4 Alkoxy group, C 1-4 It is an alkylcarbonylamino group or a halogen, The base is one of the following selected from adenine, guanine, cytosine, thymine, and uracil.

[0106] In some embodiments, the antisense chain of the siRNA modifier has one of the following modification forms A to H: [Table 1] TIFF2026182852000003.tif227164TIFF2026182852000004.tif86164 and / or the sense chain uses one of the following modification forms a to c: [Table 2] Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0107] In some embodiments, the antisense chain is modified in modification form A, and the sense chain is modified in modification form a.

[0108] In some embodiments, the antisense chain is modified with modification form B, and the sense chain is modified with modification form a.

[0109] In some embodiments, the antisense chain is modified with modification form C, and the sense chain is modified with modification form a.

[0110] In some embodiments, the antisense chain is modified with modification form C, and the sense chain is modified with modification form b.

[0111] In some embodiments, the antisense chain is modified with modification form D, and the sense chain is modified with modification form b.

[0112] In some embodiments, the antisense chain is modified with modification form E, and the sense chain is modified with modification form b.

[0113] In some embodiments, the antisense chain is modified with modification form F, and the sense chain is modified with modification form b.

[0114] In some embodiments, the antisense chain is modified with modification form G, and the sense chain is modified with modification form b.

[0115] In some embodiments, the antisense chain is modified with modification form H, and the sense chain is modified with modification form c.

[0116] In some embodiments, the antisense chain of the siRNA modifier has one of the following modification forms A' to G': [Table 3] TIFF2026182852000007.tif217164 and / or the sense chain may use the following modified form a' or b': [Table 4] Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0117] In some embodiments, the antisense chain is modified in modification form A', and the sense chain is modified in modification form a'.

[0118] In some embodiments, the antisense chain is modified with modification form B', and the sense chain is modified with modification form a'.

[0119] In some embodiments, the antisense chain is modified with modification form C', and the sense chain is modified with modification form a'.

[0120] In some embodiments, the antisense chain is modified with modification form C', and the sense chain is modified with modification form b'.

[0121] In some embodiments, the antisense chain is modified with modification form D', and the sense chain is modified with modification form b'.

[0122] In some embodiments, the antisense chain is modified with modification form E', and the sense chain is modified with modification form b'.

[0123] In some embodiments, the antisense chain is modified with modification form F', and the sense chain is modified with modification form b'.

[0124] In some embodiments, the antisense chain is modified with modification form G', and the sense chain is modified with modification form b'.

[0125] In some embodiments, the siRNA duplex comprises one or at least two combinations selected from the following oligonucleotide duplexes consisting of sense strand-antisense strand pairings: (1) The sense strand has the sequence shown in SEQ ID NO:426, and the antisense strand has the sequence shown in SEQ ID NO:552. (2) The sense strand has the sequence shown in SEQ ID NO:427, and the antisense strand has the sequence shown in SEQ ID NO:553. (3) The sense strand has the sequence shown in SEQ ID NO:429, and the antisense strand has the sequence shown in SEQ ID NO:555. (4) The sense strand has the sequence shown in SEQ ID NO:430, and the antisense strand has the sequence shown in SEQ ID NO:556. (5) The sense strand has the sequence shown in SEQ ID NO:431, and the antisense strand has the sequence shown in SEQ ID NO:557. (6) The sense strand has the sequence shown in SEQ ID NO:435, and the antisense strand has the sequence shown in SEQ ID NO:561. (7) The sense strand has the sequence shown in SEQ ID NO:439, and the antisense strand has the sequence shown in SEQ ID NO:565. (8) The sense strand has the sequence shown in SEQ ID NO:440, and the antisense strand has the sequence shown in SEQ ID NO:566. (9) The sense strand has the sequence shown in SEQ ID NO:442, and the antisense strand has the sequence shown in SEQ ID NO:568. (10) The sense strand has the sequence shown in SEQ ID NO:443, and the antisense strand has the sequence shown in SEQ ID NO:569. (11) The sense strand has the sequence shown in SEQ ID NO:444, and the antisense strand has the sequence shown in SEQ ID NO:570. (12) The sense strand has the sequence shown in SEQ ID NO:445, and the antisense strand has the sequence shown in SEQ ID NO:571. (13) The sense strand has the sequence shown in SEQ ID NO:446, and the antisense strand has the sequence shown in SEQ ID NO:572. (14) The sense strand has the sequence shown in SEQ ID NO:447, and the antisense strand has the sequence shown in SEQ ID NO:573. (15) The sense strand has the sequence shown in SEQ ID NO:448, and the antisense strand has the sequence shown in SEQ ID NO:574. (16) The sense strand has the sequence shown in SEQ ID NO:449, and the antisense strand has the sequence shown in SEQ ID NO:575. (17) The sense strand has the sequence shown in SEQ ID NO:450, and the antisense strand has the sequence shown in SEQ ID NO:576. (18) The sense strand has the sequence shown in SEQ ID NO:454, and the antisense strand has the sequence shown in SEQ ID NO:580. (19) The sense strand has the sequence shown in SEQ ID NO:455, and the antisense strand has the sequence shown in SEQ ID NO:581. (20) The sense strand has the sequence shown in SEQ ID NO:456, and the antisense strand has the sequence shown in SEQ ID NO:582. (21) The sense strand has the sequence shown in SEQ ID NO:468, and the antisense strand has the sequence shown in SEQ ID NO:594. (22) The sense strand has the sequence shown in SEQ ID NO:471, and the antisense strand has the sequence shown in SEQ ID NO:597. (23) The sense strand has the sequence shown in SEQ ID NO:477, and the antisense strand has the sequence shown in SEQ ID NO:603. (24) The sense strand has the sequence shown in SEQ ID NO:478, and the antisense strand has the sequence shown in SEQ ID NO:604. (25) The sense strand has the sequence shown in SEQ ID NO:479, and the antisense strand has the sequence shown in SEQ ID NO:605. (26) The sense strand has the sequence shown in SEQ ID NO:480, and the antisense strand has the sequence shown in SEQ ID NO:606. (27) The sense strand has the sequence shown in SEQ ID NO: 529, and the antisense strand has the sequence shown in SEQ ID NO: 655. (28) The sense strand has the sequence shown in SEQ ID NO: 530, and the antisense strand has the sequence shown in SEQ ID NO: 656. (29) The sense strand has the sequence shown in SEQ ID NO: 532, and the antisense strand has the sequence shown in SEQ ID NO: 658.

[0126] In some embodiments, the nucleotides from the 5' end to positions 2 through 8 of the antisense strand are each independently modified nucleotides, and these modified nucleotides are UNA or GNA, or the nucleotides from the 5' end to positions 2 through 8 of the antisense strand are each independently DNA, where the structures of UNA and GNA are as follows: [ka] Here, the base is selected from adenine, guanine, cytosine, thymine, and uracil.

[0127] In some embodiments, the 3' end of the sense strand or antisense strand is an inverted modified nucleotide, or the 6th or 7th position of the 5' end of the sense strand is an inverted modified nucleotide, where the modified nucleotide is selected from dAinV, dTinV, dGinV and dCinV having the following structures. [ka]

[0128] In some embodiments, the siRNA duplex comprises one or at least two combinations selected from the following oligonucleotide duplexes consisting of sense strand-antisense strand pairings: (1) The sense strand has the sequence shown in SEQ ID NO:677, and the antisense strand has the sequence shown in SEQ ID NO:686. (2) The sense strand has the sequence shown in SEQ ID NO:678, and the antisense strand has the sequence shown in SEQ ID NO:687. (3) The sense strand has the sequence shown in SEQ ID NO:683, and the antisense strand has the sequence shown in SEQ ID NO:693. (4) The sense strand has the sequence shown in SEQ ID NO:680, and the antisense strand has the sequence shown in SEQ ID NO:689.

[0129] The double-stranded ribonucleic acid and double-stranded ribonucleic acid modifiers of this disclosure can be optionally linked to one or more conjugate groups to form a double-stranded ribonucleic acid conjugate. The conjugate group may be attached to the sense strand, antisense strand, or both strands at the 3' end, 5' end, or both ends. For example, the conjugate group may be linked to the sense strand. In a preferred embodiment, the conjugate group is linked at the 3' end of the sense strand. In one embodiment, the conjugate group has an arbitrary GalNAc structure.

[0130] This disclosure provides an siRNA conjugate comprising an siRNA duplex described herein and a conjugate group ligated to the siRNA duplex.

[0131] In some embodiments, the conjugate group is linked at the 3'-terminus or 5'-terminus of the sense chain, preferably at the 3'-terminus.

[0132] In some embodiments, the conjugate group is one or more GalNAcs or derivatives thereof that are added using divalent or trivalent branched linker arms.

[0133] Generally, the conjugate group comprises at least one pharmaceutically acceptable targeting group, or further comprises a linker, and the siRNA, the linker, and the targeting group are linked in sequence. In some embodiments, there are 1 to 6 targeting groups. In some embodiments, there are 2 to 4 targeting groups. In some embodiments, there are 3 targeting groups. The conjugate group may be covalently or noncovalently linked to the siRNA molecule, and the linking site may be at the 3' or 5' end of the siRNA sense strand, at the 5' end of the antisense strand, or in the internal sequence of the siRNA. In some embodiments, the linking site is at the 3' end of the siRNA sense strand.

[0134] In some embodiments, the pharmaceutically acceptable targeting group may be a common ligand in the field of siRNA administration, such as the various ligands described in WO2009082607A2, which are incorporated herein by reference as a whole.

[0135] In some embodiments, each ligand is independently selected from a single ligand capable of binding to a cell surface receptor. In some embodiments, at least one ligand is capable of binding to a hepatocyte surface receptor. In some embodiments, at least one ligand is capable of binding to a mammalian cell surface receptor. In some embodiments, at least one ligand is capable of binding to a human hepatocyte surface receptor. In some embodiments, at least one ligand is capable of binding to the hepatocyte surface asialoglycoprotein receptor (ASGPR). The types of these ligands are well known to those skilled in the art, and their role is generally to bind to specific receptors on the surface of target cells and to mediate the delivery of ligand-linked siRNA to the target cells.

[0136] In some embodiments, the pharmaceutically acceptable targeting group in the siRNA conjugate may be galactose or N-acetylgalactosamine, where the galactose or N-acetylgalactosamine molecule may be monovalent, divalent, trivalent, or tetravalent. That is, after the siRNA molecule and the conjugate group containing the targeting group, galactose or N-acetylgalactosamine molecule, form an siRNA conjugate, the molar ratio of the siRNA molecule to the galactose or N-acetylgalactosamine molecule in the siRNA conjugate is 1:1, 1:2, 1:3, or 1:4. In some embodiments, when the siRNA is conjugated to a conjugate group containing N-acetylgalactosamine, the N-acetylgalactosamine molecule is trivalent.

[0137] The targeting group may be linked to the siRNA molecule via a suitable linker, and those skilled in the art can select a suitable linker depending on the specific type of targeting group. These linkers, types of targeting groups, and methods of linking with siRNA may be referenced from the disclosure of WO2015006740A2, which is incorporated herein by reference as a whole.

[0138] In some embodiments, the structure of the conjugate group is, for example, [ka] And, Here, X is a hydroxyl protecting group or H, the hydroxyl protecting group is selected from an acetyl group, a benzoyl group or an isobutyryl group, Y is an amine protecting group or H, the amine protecting group is selected from a formyl group, an acetyl group, a propionyl group, an n-butyryl group or an isobutyryl group, n is an integer from 0 to 20, and q, r and s are independently integers from 1 to 7.

[0139] In some embodiments, the structure of the conjugate group is, for example, [ka] That is the case.

[0140] In some embodiments, the structure of the conjugate group is, for example, [ka] Here, X is oxygen, -N(Y)-, or sulfur. Y is C 1-4 Alkyl alkyl group or C 6-10 It is an aryl group, R1 is oxygen or sulfur. R2 is hydrogen, -NH2, C 1-4 Alkyl alkyl group, C 6-10 Aryl group, C 1-4 It is an alkoxy group or halogen, A is -(CH2)a -, -(CH2CH2O) b -, -((CH2) c NHCO) d - or -((CH2) c CONH) d -, where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5, B is -(CH2) e -, where e is an integer from 0 to 7, L is -CONH- or -NHCO-, X1 is -(CH2) f - or -(CH2CH2O) f CH2-, and f is an integer from 1 to 5, X2 is -(CH2) g -, and g is an integer from 1 to 6, X3 is oxygen or sulfur, Y1 is 0 or 1, Y2 is 0, 1 or 2, when Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; when Y3 is 3, X3 is carbon, m is an integer from 0 to 4, n is an integer from 0 to 4.

[0141] In some embodiments, the conjugate group is, for example, [Chemical Formula] has any one of the structures:

[0142] In some embodiments, the siRNA conjugate is, for example, [Chemical Formula] has any one of the structures:

[0143] In some embodiments, the conjugate group is, for example, [ka] It has the following structure, where X is oxygen, -N(Y)-, or sulfur. Y is C 1-4 Alkyl alkyl group or C 6-10 It is an aromatic group, R1 is oxygen or sulfur. R2 is hydrogen, -NH2, C 1-4 Alkyl alkyl group, C 6-10 Aryl group, C 1-4 It is an alkoxy group or halogen, A is -(CH2) a -,-(CH2CH2O) b -,-((CH2) c NHCO) d -or-((CH2) c CONH) d -where a is an integer between 1 and 15, b is an integer between 1 and 7, c is an integer between 1 and 7, and d is an integer between 1 and 5. B is -(CH2) e - where e is an integer from 0 to 7, L is -CONH- or -NHCO-, X1 is -(CH2) f -or-(CH2CH2O) f CH2-, where f is an integer from 1 to 5. X2 is -(CH2) g - and g is an integer from 1 to 6. X3 is oxygen or a resource. Y1 is either 0 or 1. Y2 is 0, 1, or 2. When Y3 is 1, X4 is CH2; when Y3 is 2, X4 is CH; and when Y3 is 3, X3 is carbon. m is an integer between 0 and 4. n is an integer between 0 and 4. q is an integer between 0 and 4.

[0144] In some embodiments, the conjugate group is, for example, [ka] It has one of the following structures.

[0145] In some embodiments, the siRNA conjugate of this disclosure is, for example, [ka] It has one of the following structures: TIFF2026182852000019.tif143170.

[0146] In some embodiments, the conjugate group is G101.

[0147] In some embodiments, the siRNA conjugate comprises one or at least two combinations selected from oligonucleotide double hedges consisting of the following sense strand-antisense strand pairings: (1) The sense strand has the sequence shown in SEQ ID NO:695, and the antisense strand has the sequence shown in SEQ ID NO:732. (2) The sense strand has the sequence shown in SEQ ID NO:706, and the antisense strand has the sequence shown in SEQ ID NO:743. (3) The sense strand has the sequence shown in SEQ ID NO:707, and the antisense strand has the sequence shown in SEQ ID NO:744. (4) The sense strand has the sequence shown in SEQ ID NO:708, and the antisense strand has the sequence shown in SEQ ID NO:745. (5) The sense strand has the sequence shown in SEQ ID NO:710, and the antisense strand has the sequence shown in SEQ ID NO:747. (6) The sense strand has the sequence shown in SEQ ID NO:713, and the antisense strand has the sequence shown in SEQ ID NO:750. (7) The sense strand has the sequence shown in SEQ ID NO:714, and the antisense strand has the sequence shown in SEQ ID NO:751. (8) The sense strand has the sequence shown in SEQ ID NO:715, and the antisense strand has the sequence shown in SEQ ID NO:752. (9) The sense strand has the sequence shown in SEQ ID NO:719, and the antisense strand has the sequence shown in SEQ ID NO:756. (10) The sense strand has the sequence shown in SEQ ID NO:720, and the antisense strand has the sequence shown in SEQ ID NO:757. (11) The sense strand has the sequence shown in SEQ ID NO:721, and the antisense strand has the sequence shown in SEQ ID NO:758. (12) The sense strand has the sequence shown in SEQ ID NO:722, and the antisense strand has the sequence shown in SEQ ID NO:759. (13) The sense strand has the sequence shown in SEQ ID NO:723, and the antisense strand has the sequence shown in SEQ ID NO:760. (14) The sense strand has the sequence shown in SEQ ID NO:724, and the antisense strand has the sequence shown in SEQ ID NO:761. (15) The sense strand has the sequence shown in SEQ ID NO:725, and the antisense strand has the sequence shown in SEQ ID NO:762. (16) The sense strand has the sequence shown in SEQ ID NO:728, and the antisense strand has the sequence shown in SEQ ID NO:765. (17) The sense strand has the sequence shown in SEQ ID NO:729, and the antisense strand has the sequence shown in SEQ ID NO:766.

[0148] This disclosure further provides a nucleic acid protein complex comprising the aforementioned siRNA double strand or siRNA conjugate double strand or antisense strand of the double strand, and a nuclease.

[0149] In this disclosure, the term "nucleic acid-protein complex" refers to the RNA-induced silencing complex (RISC) formed by the binding of siRNA and Argonaute protein (AGO). Subsequently, the siRNA is decomposed into a sense strand and an antisense strand. The sense strand is degraded, and the antisense strand (guide strand) RISC binds to a target mRNA homologous to the siRNA via base pairing. RISC has nuclease function, and the siRNA guides RISC to cleave homologous single-stranded mRNA, rendering the mRNA dysfunctional, that is, preventing protein translation and production, thus "silencing" the gene.

[0150] This disclosure further provides recombinant vectors, which include nucleic acid molecules encoding siRNA described in the disclosure.

[0151] In some embodiments, the vector skeleton of the recombinant vector is selected from recombinant viroid-derived circular RNA vectors, tRNAs, rRNA scaffolds, and chimeric tRNA / pre-mi RNA vectors.

[0152] This disclosure further provides recombinant cells, which include the aforementioned siRNA or recombinant vector.

[0153] In some embodiments, the recombinant cells are selected from Rhodopseudomonas sulfidophila and ribonuclease III-deficient Corynebacterium glutamicum.

[0154] As used herein, “recombinant vector” is preferably a vector of a regulatory sequence operably linked to a nucleotide sequence, the nucleotide sequence encoding the sense strand contained in the nucleic acid molecule of the present invention. “Recombinant cell” is a cell into which at least one recombinant vector capable of expressing the nucleic acid molecule or at least one strand of the nucleic acid molecule has been introduced.

[0155] This disclosure further provides a method for preparing the siRNA described herein, the method comprising culturing the aforementioned recombinant cells or directly obtaining the siRNA by chemical synthesis and mixing.

[0156] This disclosure further provides a pharmaceutical composition comprising the siRNA double strand or applicable siRNA conjugate and a pharmaceutically acceptable carrier.

[0157] In one embodiment, this specification provides a pharmaceutical composition containing the siRNA and a pharmaceutically acceptable carrier described herein. The pharmaceutical composition containing the siRNA can be used to treat diseases or conditions related to the expression or activity of the FXI gene, such as hypertension. Such pharmaceutical compositions are prepared based on a delivery model. One example is a composition prepared for parenteral delivery, for example, systemic administration by subcutaneous injection (SC) delivery. Another example is a composition prepared for direct delivery to the brain parenchyma, for example, infusion into the brain, for example, continuous pump infusion.

[0158] The pharmaceutical compositions comprising siRNA in this disclosure may be, for example, solutions with or without a buffer, or compositions containing a pharmaceutically acceptable carrier. Such compositions include, for example, aqueous or crystalline compositions, liposomal formulations, micelle formulations, emulsions, and gene therapy vectors.

[0159] In the method of this disclosure, the siRNA can be administered in solution. Free siRNA can be administered in an unbuffered solution, such as physiological saline or water. Alternatively, the free siRNA can be administered in a suitable buffer solution. The buffer solution may contain acetate, citrate, prolamin, carbonate, or phosphate, or any combination thereof. In one preferred embodiment, the buffer solution is phosphate-buffered saline (PBS). The pH and volumetric osmotic concentration of the buffer containing the siRNA can be adjusted to suit administration to the subject.

[0160] In some embodiments, the buffer solution further comprises a reagent for controlling the osmotic molar concentration of the solution, thereby maintaining the osmotic molar concentration at a desired value, such as the physiological value of human plasma. Solutes that may be added to the buffer solution to control the osmotic molar concentration include (but are not limited to) proteins, peptides, amino acids, non-metabolic polymers, vitamins, ions, sugars, metabolites, organic acids, lipids, or salts. In some embodiments, the reagent for controlling the osmotic molar concentration of the solution is a salt. In some embodiments, the reagent for controlling the osmotic molar concentration of the solution is sodium chloride or potassium chloride.

[0161] The pharmaceutical compositions of this disclosure can be administered in doses sufficient to suppress the expression of the FXI gene. Generally, appropriate doses of the siRNAs of this disclosure range from about 0.001 to about 200.0 milligrams per kilogram of body weight per day of the recipient, and generally range from about 1 to 50 mg per kilogram of body weight per day. For example, siRNAs (e.g., dsRNAs) are available in single doses of about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3. 4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7 , 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, It can be administered at doses of 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 31, 32, 33, 34, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or approximately 50 mg / kg.

[0162] The pharmaceutical composition can be administered once daily, or multiple times at different time intervals over a period of 1 to 365 days, or the siRNA can be administered as two, three, or more subdoses at appropriate intervals within one year, or it can be administered by continuous infusion or delivery using a sustained-release formulation. In such cases, the amount of siRNA contained in each subdose must be correspondingly small in order to achieve the total daily dose. For example, dose units can be formulated for delivery over several days using a conventional sustained-release formulation that provides sustained siRNA release over several days. Sustained-release formulations are well known in the art and are particularly useful for delivering reagents to specific sites, and can therefore be used with the reagents of this disclosure. In this example, the dose unit comprises a plurality of applicable daily doses.

[0163] In other embodiments, a single dose of the pharmaceutical composition may be sustained for a long period, thereby allowing subsequent administrations to occur at intervals of 3, 4, or 5 days or 1, 2, 3, or 4 weeks. In some embodiments of the Disclosure, the pharmaceutical composition of the Disclosure is administered once weekly in a single dose. In other embodiments of the Disclosure, the pharmaceutical composition of the Disclosure is administered once every two months in a single dose.

[0164] Those skilled in the art will understand that several factors can influence the dose and schedule required for the effective treatment of a subject, including (but not limited to) the severity of the disease or condition, previous treatments, the subject's overall health status and / or age, and other comorbidities. Treating a subject with a therapeutically effective dose of a composition may include a single treatment or a series of treatments. As described elsewhere in this specification, the effective dose and in vivo half-life of each siRNA contained herein can be estimated based on conventional methods or in vivo studies using appropriate animal models.

[0165] Depending on whether local or systemic treatment is desired and the area to be treated, the pharmaceutical compositions of this disclosure can be administered in many ways. Administration may be local (e.g., by a skin patch), transpulmonary, including by inhalation or blowing of powder or aerosol, including through a sprayer, intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, subdermal, for example, via an implantable device, or intracranial, for example, intracerebral, intrathecal or intraventricular administration.

[0166] siRNA for use in the compositions and methods of this disclosure can be prepared for delivery in membrane-bound molecular assemblies, such as liposomes or micelles. As used herein, the term “liposome” refers to a vesicle composed of amphiphilic lipids placed on at least one lipid bilayer (e.g., one or more lipid bilayers), having an outer membrane formed of a lipophilic material and an internal aqueous portion. The lipophilic material typically separates the aqueous interior from the aqueous exterior (which may be included in some examples) that does not contain the siRNA composition. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposome membrane is structurally similar to that of a biological membrane, when a liposome is administered to a tissue, the bilayer of the liposome fuses with the bilayer of the cell membrane. As the fusion of the liposome and the cell progresses, the internal aqueous contents containing the siRNA are delivered into the cell, where the siRNA can specifically bind to target RNA and mediate RNA interference (RNAi).

[0167] Liposomes containing siRNA can be prepared by various methods. In one example, the lipid component of the liposome is dissolved in a detergent to form micelles with the lipid component. For example, the lipid component may be an amphiphilic cationic lipid or a lipid conjugate. The detergent may have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholates, CHAPS, octyl glucoside, deoxycholate, and lauroyl sarcosine. The siRNA formulation is then added to the micelles containing the lipid component. The cationic groups on the lipid interact with the siRNA and condense around the siRNA to form liposomes. After condensation, the detergent is removed, for example, by dialysis, to obtain the corresponding liposome formulation of siRNA.

[0168] siRNA, for example, the siRNA double strands of this disclosure, can be fully packaged in a lipid formulation (e.g., LNP or other nucleic acid-lipid particles).

[0169] As used herein, the term "LNP" refers to stable nucleic acid-lipid particles. LNPs contain cationic lipids, non-cationic lipids, and lipids that prevent aggregation of the particles (e.g., PEG-lipid conjugates). LNPs are very useful in synthetic applications because they exhibit an extended cycle life after intravenous (iv) injection and accumulate at distal sites (e.g., sites physically distant from the injection site).

[0170] In one example, the mass ratio of lipids to siRNA double strands is approximately 1:1 to 50:1, approximately 1:1 to 25:1, approximately 3:1 to 15:1, approximately 4:1 to 10:1, approximately 5:1 to 9:1, or approximately 6:1 to 9:1.

[0171] In some preferred embodiments, the lipid nanoparticles include cationic lipids, neutral lipids, structural lipids, and polymer-conjugated lipids.

[0172] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (I), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where G1 is C 1~6 It is an alkylene group, and G2 is C 2~8 It is an alkylene group, and G3 is C 1~3 It is an alkylene group, and L1 is C 6~15 It is a linear alkyl group, and L2 is C 12~25 It is a branched alkyl group. For example, YK-009 has the structure of formula (II) (see Patent CN114044741B, all of which are incorporated herein by reference, including the general formula and specific compounds therein). [ka]

[0173] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (II), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where G1 is C 2~8 It is an alkylene group, and G2 is C 2~8 It is an alkylene group, where L1 is -C(O)O- or -OC(O)-, L2 is -C(O)O- or -OC(O)-, and R1 is C 6~25 It is a linear or branched alkyl group, and R2 is C 6~25 The alkyl group is linear or branched, where G3 is HO(CH2)2- or HO(CH2)3-, G4 is HO(CH2)2- or HO(CH2)3-, and L is (CH2)2- or -(CH2)3- or -(CH2)4-. For example, YK-401 has the structure of formula (II-I), YK-402 has the structure of formula (II-II), and YK-407 has the structure of formula (II-III) (see Patent CN115784921B, all of which are incorporated herein by reference, in particular the general formulas and specific compounds therein). [ka]

[0174] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (III), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where G1 is C 1~6 It is an alkylene group, and G2 is C 2~8 It is an alkylene group, and R1 is C 6~20 It is a linear or branched alkyl group, and R2 is C 12~25 The branched alkyl group G3 is HO(CH2)2N(CH3)(CH2)2-, HO(CH2)2N(CH2CH3)(CH2)2-, (HO(CH2)2)2N(CH2)2-, CH3O(CH2)2N(CH3)(CH2)2-, (CH3)2N(CH2)3SC(O)O(CH2)2-, (CH3)2N(CH2)3SC(O)-, CH3NH(CH2)2N(CH3)(CH2)2-, or CH3CH2NH(CH2)2-. For example, YK-201 has the structure of formula (III-I), YK-202 has the structure of formula (III-II), etc. (See Patent CN115677518B, all the contents of that patent document are incorporated herein by reference, in particular the general formula and specific compounds therein). [ka]

[0175] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (IV), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where G1 is C 1~8 It is an alkylene group, and G2 is C 2~8 It is an alkylene group, and R1 is C 6~25 It is a linear or branched alkyl group, and R2 is C 12~25The alkyl group is either linear or branched, where G3 is HO(CH2)2N(R3)CH2CH(OH)CH2-, where R3 is -CH3, -CH2CH3, or -CH2CH2OH. Examples include YK-305 with the structure of formula (IV-I) and YK-310 with the structure of formula (IV-II) (see Patent CN115745820B, all of which are incorporated herein by reference, in particular the general formulas and specific compounds therein). [ka]

[0176] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (V), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where G 1 and G 2 These are, independently, unsubstituted C6-C 10 It is an alkylene group, G 3 This is an unsubstituted C1-C 12 It is an alkylene group, R 1 and R 2 These are, independently, C6-C 24 Alkyl alkyl group or C6-C 24 It is an alkenyl group, R 3 is OR 5 , N, -C(=O)OR 4 -OC(=O)R 4 or -NR 5 C(=O)R 4 And R 4 C1-C 12 It is a hydrocarbon group and R 5 is an H or C1-C6 hydrocarbon group, such as ALC0315 having the structure of formula (VI) (see Patent CN108368028B, all of which are incorporated herein by reference, including the general formula and specific compounds therein). [ka]

[0177] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (VI), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer, where R4 is -(CH2) n Q and -(CH2) n Selected from CHQR, where Q is -OR, -OH, -O(CH2) n N(R)2, -OC(O)R, -CX3, -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O)2R, -N(H)S(O)2R, -N(R)C(O )N(R)2, -N(H)C(O)N(R)2, -N(H)C(O)N(H)(R), -N(R)C(S)N(R)2, -N(H)C(S)N(R)2, -N(H)C(S )Selected from the group consisting of N(H)(R), -N(R)S(O)2R8 and heterocycles, where n is 1, 2, or 3, for example, SM102 of the structure of formula (VI-I) (see patent application CN110520409A, all contents of which are incorporated herein by reference, in particular the general formula and specific compounds therein). [ka]

[0178] In some preferred embodiments, the cationic lipid is a compound having the structure of formula (VII), or its N-oxide, solvate, pharmaceutically acceptable salt, or stereoisomer (see Patent CN102625696B, DLIN-MC3-DMA (as shown in formula (VII)), all of which are incorporated herein by reference, in particular the general formula and specific compounds therein), [ka]

[0179] In some more preferred embodiments, the cationic lipid is one or at least two selected from the group consisting of YK-009, YK-407, YK-305, ALC0315, SM102, and DLIN-MC3-DMA.

[0180] In some preferred embodiments, the molar ratio of the cationic lipid to the neutral lipid is 1:1 to 10:1.

[0181] In some preferred embodiments, the molar ratio of the cationic lipid to the structural lipid is 1:1 to 5:1.

[0182] In some preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is (25-65):(5-25):(25-70):(0.5-5).

[0183] In some preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is (25-65):(5-25):(25-45):(0.5-5).

[0184] In some more preferred embodiments, the molar ratio of the cationic lipid, the neutral lipid, the structural lipid, and the polymer-conjugated lipid is 50:10:38.5:1.5 or 49:10:39.5:1.5.

[0185] In some preferred embodiments, the neutral lipid is one or at least two selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol, and derivatives thereof.

[0186] In some more preferred embodiments, the neutral lipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuxinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-difytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoylphosphatidylethanolamine It is one or at least two selected from the group consisting of lysophosphate (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-stearoylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE), and mixtures thereof.

[0187] In some more preferred embodiments, the neutral lipid is DOPE and / or DSPC.

[0188] In some preferred embodiments, the structural lipid is one or at least two selected from the group consisting of cholesterol, nonsterols, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, α-tocopherol, and corticosteroids.

[0189] In some more preferred embodiments, the structural lipid is cholesterol.

[0190] In some preferred embodiments, the polymer-conjugated lipid is one or at least two selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.

[0191] In some more preferred embodiments, the polymer-conjugated lipid is one or at least two selected from the group consisting of distearoylphosphatidylethanolamine polyethylene glycol 2000 (DSPE-PEG2000), dimyristoylglycero-3-methoxypolyethylene glycol 2000 (DMG-PEG2000), and methoxypolyethylene glycol ditetradecylacetamide (ALC-0159).

[0192] Examples of the pharmaceutical compositions of this disclosure include, but are not limited to, aqueous formulations, emulsion formulations, and liposome-containing formulations. These compositions can be produced from a variety of components, examples of which include, but are not limited to, preformed liquids, self-emulsifying solids, and self-emulsifying semi-solids. Preferably, for example, when treating hepatic diseases (e.g., liver cancer), the formulations target the liver.

[0193] The pharmaceutical formulations of this disclosure (which may conveniently be available in unit dosage forms) can be manufactured according to prior art well known in the pharmaceutical industry. Such art includes the step of combining these active ingredients with the pharmaceutical carrier or excipients. Generally, these formulations are manufactured by the step of uniformly and finely combining the active ingredients with a liquid carrier or a finely dispersed solid carrier or both, and, if necessary, then forming the product.

[0194] The compositions of this disclosure can be prepared as any of many possible dosage forms, including, but not limited to, tablets, capsules, gelatin capsules, liquid syrups, soft capsules, suppositories, and enemas. The compositions of this disclosure can also be prepared as suspensions in aqueous, non-aqueous, or mixed media. The aqueous suspension may further contain substances that increase the viscosity of the suspension, such substances including, for example, sodium carboxymethylcellulose, sorbitol, and / or dextran. The suspension may further contain stabilizers.

[0195] Some compositions of this disclosure also incorporate a carrier compound into the formulation. As used herein, “carrier compound” or “carrier” may refer to a nucleic acid or its analogue, which is inert (i.e., not biologically active in itself) but is recognized as a nucleic acid in bodily processes and reduces the bioavailability of biologically active nucleic acids, for example, by degrading biologically active nucleic acids or facilitating their removal from circulation. Co-administration of nucleic acids and carrier compounds (generally in excess of the latter) can result in a significant reduction in the amount of nucleic acid recovered in the liver, kidneys or other extracorporeal circulation reservoirs, which is thought to be due to competition for a common receptor between the carrier compound and the nucleic acid. For example, co-administration with polyinosinic acid, dextran sulfate, polycytidylic acid, or 4-acetamide-4'isothiocyanatostilbene-2,2'-disulfonic acid can reduce the recovery of some phosphorothioate-modified dsRNAs in liver tissue (Miyao et al., DsRNA Research and Development, 1995, 5, 115-121; Takakura et al., DsRNA & Nucleic Acid Drug Development, 1996, 6, 177-183).

[0196] Compared to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspension, or any other pharmaceutically inert medium for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid, and when combined with nucleic acids and other components of a particular pharmaceutical composition, the excipient is selected to provide the desired volume, consistency, etc., with reference to the intended method of administration. Typical pharmaceutical carriers include, but are not limited to, adhesives (e.g., pregelatinized corn starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose), fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethylcellulose, polyacrylate, or calcium hydrogen phosphate), lubricants (e.g., magnesium stearate, talc, silica, colloidal silica, stearic acid, metal stearates, hydrogenated vegetable oils, corn starch, polyethylene glycol, sodium benzoate, sodium acetate), disintegrants (e.g., starch, sodium starch glycolate), and wetting agents (e.g., sodium lauryl sulfate).

[0197] pharmaceutically acceptable organic or inorganic excipients that do not react toxicly with nucleic acids and are suitable for parenteral administration may also be used to prepare the compositions of this disclosure. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, and polyvinylpyrrolidone.

[0198] Formulations for topical administration of nucleic acids may include sterile or non-sterile aqueous solutions in a common solvent such as alcohol, non-aqueous solutions, or nucleic acid solutions in a liquid or solid oil matrix. These solutions may further include buffers, diluents, and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients that do not react toxicly with nucleic acids and are suitable for parenteral administration may be used.

[0199] Suitable pharmaceutically acceptable excipients include, but are not limited to, water, saline solutions, alcohols, polyethylene glycol, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethyl cellulose, polyvinylpyrrolidone and the like.

[0200] The present disclosure further provides methods for treating or preventing diseases and conditions that can be modulated by downregulating FXI gene expression. For example, thrombotic diseases including deep vein thrombosis, venous or arterial thrombosis, ischemic stroke, pulmonary embolism, myocardial infarction, stroke, Alzheimer's disease, thrombosis associated with chronic kidney disease or end-stage renal failure.

[0201] The siRNA of the present disclosure can be administered to a subject using any mode of administration known in the art, including but not limited to subcutaneous, intravenous, intramuscular, intraocular, intrabronchial, intrapleural, intraperitoneal, intraarterial, lymphatic, cerebrospinal, and any combinations thereof. In a preferred embodiment, these reagents are administered subcutaneously.

[0202] In another embodiment, the siRNA is administered in combination with another therapeutic agent. The siRNA and the additional therapeutic agent can be administered in combination in the same composition, for example, administered parenterally, or the additional therapeutic agent can be administered as part of a separate composition or by another method described herein.

[0203] Examples of other therapeutic agents include known agents for the treatment of thrombotic disorders or known agents for the treatment of cardiovascular disorders, such as anticoagulants, antiplatelet agents and thrombolytic agents for acute myocardial infarction and pulmonary embolism, and other drugs. Here, anticoagulants include warfarin, heparin, low molecular weight heparin (e.g., enoxaparin), and direct oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban, edoxaban); antiplatelet agents include aspirin, clopidogrel, ticagrelor, and prasugrel; thrombolytic agents for acute myocardial infarction and pulmonary embolism include alteplase, tenecteplase, and streptokinase; and other drugs include fondaparinux sodium and bivalirudin.

[0204] In one embodiment, siRNA is administered to a patient, and then another therapeutic agent is administered to the same patient (or vice versa). In another embodiment, siRNA and another therapeutic agent are administered simultaneously.

[0205] The following examples are for illustrative purposes only and are not intended to limit the scope of the disclosure. Unless otherwise specified, the technical solutions used in the examples are common methods well known to those skilled in the art, and the raw materials used are all commercially available.

[0206] The abbreviations for nucleotides used in this specification are as follows:

[0207] A = Adenosine-3'-phosphate Am=2'-methoxyadenosine-3'-phosphate Ams = 2'-methoxyadenosine-3'-phosphorothioate Af = 2'-fluoroadenosine-3'-phosphate Afs = 2'-fluoroadenosine-3'-phosphorothioate dA = 2'-deoxyadenosine-3'-phosphate dAs = 2'-deoxyadenosine-3'-phosphorothioate G = Guanosine-3'-phosphate Gm = 2'-methoxyguanosine-3'-phosphate Gms = 2'-methoxyguanosine-3'-phosphorothioate Gf = 2'-fluoroguanosine-3'-phosphate Gfs = 2'-fluoroguanosine-3'-phosphorothioate dG = 2'-deoxyguanosine-3'-phosphate dGs = 2'-deoxyguanosine-3'-phosphorothioate C = cytidine-3'-phosphate Cm = 2'-methoxycytidine-3'-phosphate Cms = 2'-methoxycytidine-3'-phosphorothioate Cf = 2'-fluorocytidine-3'-phosphate Cfs = 2'-fluorocytidine-3'-phosphorothioate dC = 2'-deoxycytidine-3'-phosphate dCs = 2'-deoxycytidine-3'-phosphorothioate U = uridine-3'-phosphate Um = 2'-methoxyuridine-3'-phosphate Ums = 2'-methoxyuridine-3'-phosphorothioate Uf = 2'-fluorouridine-3'-phosphate Ufs = 2'-fluorouridine-3'-phosphorothioate dU = 2'-deoxyuridine-3'-phosphate dUs = 2'-deoxyuridine-3'-phosphorothioate AmsEVP = 5'-vinyl-(E)-phosphonate-2'-methoxyadenosine-3'-phosphorothioate UmsEVP = 5'-vinyl-(E)-phosphonate-2'-methoxyuridine-3'-phosphorothioate dAinV = (3'-3' linked)2'-deoxyadenosine-3'-phosphate dTinV = (3'-3' linked)2'-deoxythymidine-3'-phosphate Agna=adenosine-diol nucleic acid Cgna=cytidine-diol nucleic acid Ggna=guanosine-diol nucleic acid Tgna=thymidine-diol nucleic acid Ugna=uridine-diol nucleic acid

[0208] Examples of the coding rules for siRNA motifs (or motifs), siRNA modifications, siRNA conjugates and the like in the present specification are as follows.

[0209] A motif is an unmodified RNA sequence. For sequences where the lengths of the sense strand and antisense strand are 20 / 22 bases respectively, in contrast to sequences where the lengths of the sense strand and antisense strand are 21 / 23 bases respectively, an "s" is added after the number representing the position for distinction, for example, compound B00211s.

[0210] For sequences having alternating modifications of 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F), "-AL" is added after the motif number. For example, the code of the alternating modified product B00211 is B00211-AL.

[0211] For example, for the siRNA modifications appearing in Table 7 of Example 1, when modification is performed using the modification templates DV25P, DV26P, DV27P, DV29P, DV32P, DV34P, DV39P, DV40P, DV25SP, DV26SP, DV27SP, DV29SP, DV32SP, DV34SP, DV39SP and DV40SP disclosed in the present specification, the corresponding coding rule is to change the first letter of the number code of the corresponding siRNA motif of the siRNA modification from "B" to "C", and add the corresponding template name of the siRNA modification after the number. For example, for the B00211 sequence modified using the DV25P template, the number is C00211-DV25P.

[0212] For example, with respect to the siRNA modifiers in Table 8 of Example 1, if the modification templates of this disclosure are used and off-target prevention and / or inversion modification forms may be used in addition, the applicable coding rule is to change the first letter of the code of the relevant motif of the siRNA modifier from "B" to "C", and to sequentially add the applicable template name and / or off-target prevention / inversion modification name (if any) after the code. For example, for motif B00211, the code of the modifier obtained after using the DV25P template modification and the inversion modification InV is C00211-DV25PInVG101.

[0213] For example, the siRNA conjugates appearing in Table 8 of Example 1 may use the modification templates disclosed herein, and may also use off-target prevention or inversion modification forms. For siRNA modifiers whose sense strand includes inversion modification, the conjugate group is linked at the 5' end of the sense strand, and for siRNA modifiers whose sense strand does not include inversion modification, the conjugate group is linked at the 3' end of the sense strand. The coding rule is to change the first letter of the code of the relevant motif from "B" to "D", add the relevant template name and off-target prevention / inversion modification name (if any) after the code, and add the conjugate group name such as "G103" or "G101" at the end. For example, for motif B00211, the code of the conjugate obtained after using the DV25P template modification and inversion modification InV, and linking the conjugate group G101, is D00211-DV25PInVG101. See the table below for coding examples.

[0214] [Table 5]

[0215] Examples Other purposes, features, and advantages of this disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples (which illustrate specific embodiments of this disclosure) are provided solely for illustrative purposes, because after reading the detailed description, various modifications and modifications within the spirit and scope of this disclosure will become apparent to those skilled in the art.

[0216] The experimental techniques and methods used in these examples are all general techniques unless otherwise specified. For example, in the following examples, experimental methods for which specific conditions are not explicitly stated generally follow general conditions, such as those described in Sambrook et al., Molecular Cloning: Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or conditions recommended by the manufacturer. Unless otherwise specified, the materials and reagents used in the examples are all commercially available.

[0217] Those skilled in the art will know that in each embodiment of this disclosure, when the test substance in the experiment is an siRNA conjugate, the inhibition rate and IC50 are... 50 ,I C 40 The experimental data and results, including the inhibition rate of the relevant siRNA modifier of the siRNA conjugate, and IC50, are included. 50 ,I C 40 It can be understood that these things can be reflected. This is not difficult for those skilled in the art to understand.

[0218] Example 1: Array Design 1. Basic arrangement Based on the human FXI mRNA sequence (NM_000128.4), 106 siRNA motifs (Table 1) were designed. Here, the APC was the siFXIg1 base sequence of the compound siFXIg1M1SP, which has the highest activity as shown in patent CN113227376B, and was used as the positive reference in this study. Here, the ANC was a nonsense sequence and was used as the negative control.

[0219] [Table 6] TIFF2026182852000029.tif229164TIFF2026182852000030.tif181164

[0220] 2.siRNA modification product 2.1 Fluorine-oxygen alternating modification To enhance inhibition rate and stability, the siRNA motifs in Table 1 were alternatingly modified with 2'-methoxy (2'-OMe) and 2'-fluoro (2'-F), and a 3',5'-phosphorothioate bond was introduced between the nucleotides at the 5' and / or 3' ends. The rules for alternating modification in this disclosure are as follows: For sequences with an odd sense strand length, all odd positions on the sense strand of the corresponding alternatingly modified siRNA modifier are 2'-F modified nucleotides, and all even positions are 2'-OMe modified nucleotides; for sequences with an even sense strand length, all odd positions on the sense strand of the corresponding alternatingly modified siRNA modifier are 2'-OMe modified nucleotides, and all even positions are 2'-F modified nucleotides; and all odd positions on the antisense strand are 2'-OMe modified nucleotides, and all even positions are The shift is also a 2'-F modified nucleotide, and the sense strand has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 5' end, the antisense strand has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 5' end, and the antisense strand has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 3' end. Alternating modified siRNAs designed according to this rule are represented by adding "-AL" after the number of the original base sequence. The alternatingly modified siRNA modifiers were obtained by alternating fluorine-oxygen modification of motifs B00202-B00217, B00302-B00312, B00401-B00410, B00701-B00709, B02601-B02609, B05001-B05008, B05201-B05208, B06401-B06411, B07401-B07408, B07501-B07506 and B07901-B07908 in Table 1. The modifier labeled APC-AL was obtained by alternating fluorine-oxygen modification of the siRNA motif siFXIg1M1SP, which has the highest activity as shown in patent CN113227376B, and was used as a positive reference in this study.The modified product labeled ANC-AL is an siRNA modified product obtained by alternating fluorine-oxygen modification of the siRNA motif ANC shown in Table 1, and was used as a negative control in this study.

[0221] [Table 7] TIFF2026182852000032.tif229165TIFF2026182852000033.tif229165TIFF2026182852000034.tif229164TIFF20261828520 00035.tif230164TIFF2026182852000036.tif229165TIFF2026182852000037.tif229164TIFF2026182852000038.tif189164

[0222] 2.2 siRNA modifiers modified with a modification template 2.2.1 Qualifying Templates The modification templates in this disclosure include DV25P, DV26P, DV27P, DV29P, DV32P, DV34P, DV39P, DV40P, DV25SP, DV26SP, DV27SP, DV29SP, DV32SP, DV34SP, DV39SP, and DV40SP. DV22 is the Advanced ESC template disclosed in the prior art (fluoro moieties: positions 2, 6, 14, and 16 of the antisense chain, and positions 7, 9, 10, and 11 of the sense chain). Refer to Tables 3 to 6 for the modification templates. The modification rules are as follows:

[0223] For siRNA motifs with sense strand and antisense strand lengths of 21 / 23 bases, one of the modification forms shown in Tables 3 and 4 is used for the antisense strand and sense strand, respectively.

[0224] For siRNA motifs with sense strand and antisense strand lengths of 20 / 22 bases, one of the modification forms shown in Tables 5 and 6 is used for the antisense strand and sense strand, respectively.

[0225] The siRNA modification templates using modified forms A and a, respectively, for the antisense and sense strands are named DV25P. The siRNA modification templates using modified forms B and a, respectively, for the antisense and sense strands are named DV26P. The siRNA modification templates using modified forms C and a, respectively, for the antisense and sense strands are named DV27P. The siRNA modification templates using modified forms C and b for the antisense and sense strands, respectively, are named DV29P. The siRNA modification templates using modified forms D and b for the antisense and sense strands, respectively, are named DV32P. The siRNA modification templates using modified forms E and b for the antisense and sense strands, respectively, are named DV34P. The siRNA modification templates using modified forms F and b for the antisense and sense strands, respectively, are named DV39P. The siRNA modification templates using modified forms G and b for the antisense and sense strands, respectively, are named DV40P. The modification templates disclosed in the prior art, in which the antisense chain and sense chain use modification forms H and c respectively, are designated as DV22. The siRNA modification templates using modified forms A' and a' for the antisense and sense strands, respectively, are named DV25SP. The siRNA modification template, in which the antisense strand and sense strand use modification forms B' and a' respectively, is named DV26SP. The siRNA modification template, in which the antisense strand and sense strand use modification forms C' and a' respectively, is named DV27SP. The siRNA modification template, in which the antisense strand and sense strand use modified forms C' and b' respectively, is named DV29SP. The siRNA modification template, in which the antisense strand and sense strand use modification forms D' and b' respectively, is named DV32SP. The siRNA modification template, in which the antisense strand and sense strand use modification forms E' and b' respectively, is named DV34SP. The siRNA modification template, in which the antisense strand and sense strand use modification forms F' and b' respectively, is named DV39SP. The siRNA modification template, which uses modified forms G' and b' for the antisense and sense strands respectively, was named DV40SP.

[0226] [Table 8] TIFF2026182852000040.tif228164TIFF2026182852000041.tif88164 Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0227] [Table 9] Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0228] [Table 10] TIFF2026182852000044.tif223164 Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0229] [Table 11] Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate.

[0230] 2.2.2 siRNA modifiers modified with the modification templates of this disclosure In this experiment, siRNA motifs B00209, B00210, B00211, B00211s, B00212, B00214, B00215, B00216, B00217s, B00301, B00304, B00307, ​​B00311, B00312, B00403, B00404, B00410, and B05202 were modified with the modification templates in 2.2.1; see Table 7. Natural 5'-terminal phosphorylation or simple, direct 5'-terminal phosphorylation may undergo dephosphorylation in cells; direct 5'-terminal phosphorylated oligonucleotide chains may show 90% dephosphorylation after 2 hours of circulation in the blood and may be completely gone after 24 hours. The 5'-terminal phosphorylation design (5'-E-VP) provides improved phosphorylation effect and stability by replacing the crosslinking oxygen with E-vinylphosphonate. The 5'-terminus of the antisense chain of each modification template in this disclosure contains the 5'-E-VP phosphorylation design. In Table 7, the sequence number APC-SL is the compound siFXIg1-M1SP, which has the highest activity as shown in patent CN113227376B, and its modification form is the modification template in the original patent, which is used as a positive reference in this embodiment.

[0231] [Table 12] TIFF2026182852000047.tif226164TIFF2026182852000048.tif226164TIFF20261828520 00049.tif228164TIFF2026182852000050.tif227164TIFF2026182852000051.tif227163 TIFF2026182852000052.tif227163TIFF2026182852000053.tif228164TIFF20261828520 00054.tif227164TIFF2026182852000055.tif228164TIFF2026182852000056.tif226163 TIFF2026182852000057.tif226163TIFF2026182852000058.tif227163TIFF20261828520 00059.tif228163TIFF2026182852000060.tif227163TIFF2026182852000061.tif227163 TIFF2026182852000062.tif226163TIFF2026182852000063.tif226163TIFF20261828520 00064.tif226163TIFF2026182852000065.tif226163TIFF2026182852000066.tif216163

[0232] 2.3 Off-target prevention and inversion-modified siRNA modifiers For siRNA modifiers modified with the modification template described in section 2.2.2 above, the following six types of off-target prevention designs and three types of inversion modification designs were performed.

[0233] To effectively prevent nuclease attack on the sequence ends, this study performed inversion modifications on the siRNA modified C00211-DV25P, changing the oligonucleotide sequence end ligation from the natural 3'-5' to 3'-3' and / or 5'-5'. In this study, we attempted inversion modification of the 3' end of the sense strand (InV, number 2 in the table below), inversion modification of the 3' end of the sense strand and removal of the antisense strand overhang (InVs, number 3 in the table below), and inversion modification of the 3' end of the antisense strand (AInV, number 4 in the table below).

[0234] To mitigate off-target effects, we employed modification schemes such as seed region GNA substitution (7+ and 6+, numbers 7-8 in the table below) and DNA substitution (d7B and d7B5, numbers 9-10 in the table below), and further attempted inversion modification of the nucleotide at position 6 or 7 of the seed region (6InV and 7InV, numbers 5-6 in the table below) to design the C00211-DV25P sequence to prevent off-target effects.

[0235] [Table 13]

[0236] 2.4 siRNA Conjugate For siRNA modifiers whose sense strand includes an inversion modification, the conjugate group is linked at the 5' end of the sense strand. For siRNA modifiers that do not include an inversion modification, the conjugate group is linked at the 3' end of the sense strand. DPC-SL10 is the L10-siFXIg1M1SP with the highest activity as shown in patent CN113227376B, and its modification form is the modification template in the said patent. L10 is linked at the 3' end of its sense strand, and in this study, it is used as a positive reference. The capital P in its sequence indicates that the nucleotide adjacent to the left of the letter P is a 5'-phosphate nucleotide.

[0237] [Table 14] TIFF2026182852000069.tif228163TIFF2026182852000070.tif227163TIFF2026182852000071.tif16170

[0238] Example 2. Synthesis of siRNA compounds 2.1 Synthesis of fluorine-oxygen alternating siRNA modifiers Table 2 shows siRNA modifications with alternating fluorine-oxygen modification. Here, using the small interfering ribonucleic acid with sequence number B00202-AL as an example, its base sequence is as follows.

[0239] Sense chain: 5'-CUUAUUAAGAAUUGCAGCAAA-3' (SEQ ID NO: 1) Antisense chain: 5'-UUUGCUGCAAUUCUUAAUAAGGG-3' (SEQ ID NO: 107) The odd-numbered positions of the sense strand and the even-numbered positions of the antisense strand all use 2'-F modifications, while the other positions use 2'-OMe modifications. Furthermore, the sense strand has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 5' end, the antisense strand also has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 5' end, and the antisense strand also has 3',5'-phosphorothioate bonds between the nucleotides at positions 1 and 2 and between positions 2 and 3 from the 3' end.

[0240] Equipment and reagents: The system is a Tsingke 192P model DNA / RNA automated synthesizer, and its solid phase support is a general-purpose cross-linked polystyrene bead support, model number Primer support 5G Unylinker 350 (manufactured by Cytiva).

[0241] Manufacturing method: Solutions of the following nucleotide monomers were prepared using acetonitrile at a monomer concentration of 0.15 M: DMT-A-OMe phosphoramidite monomer (Formula 1), DMT-C-OMe phosphoramidite monomer (Formula 2), DMT-G-OMe phosphoramidite monomer (Formula 3), and DMT-U-OMe phosphoramidite monomer (Formula 4), DMT-AF phosphoramidite monomer (Formula 5), ​​DMT-CF phosphoramidite monomer (Formula 6), DMT-GF phosphoramidite monomer (Formula 7), and DMT-UF phosphoramidite monomer (Formula 8). [ka]

[0242] It was manufactured using the following steps.

[0243] By solid-phase phosphoramidite ligation, nucleotide monomers were sequentially linked in the 3'-5' direction according to the nucleotide sequence order. Each linkage of nucleotide monomers involves a four-step reaction: deprotection, coupling, oxidation or sulfidation, and hydroxyl group protection. Here, when two nucleotides are linked with a phosphate, the subsequent linkage of the nucleotide monomer involves a four-step reaction: deprotection, coupling, oxidation, and hydroxyl group protection. When two nucleotides are linked with a phosphorothioate, the subsequent linkage of the nucleotide monomer also involves a four-step reaction: deprotection, coupling, sulfidation, and hydroxyl group protection. Specifically, these are as follows:

[0244] (1) Deprotection A 3% toluene dichloroacetate solution was used as a deprotection reagent to remove the DMT protecting group, followed by washing with acetonitrile.

[0245] (2) Coupling 0.25M 5-ethylthiotetrazole was used as an activator to perform coupling of each nucleotide monomer with an acetonitrile solution, followed by washing with acetonitrile.

[0246] (3) Oxidation / Sulfidation Oxidation: Oxidation was carried out using a 0.05 M iodine-pyridine / water (90 / 10) solution as an oxidizing agent, followed by washing with acetonitrile.

[0247] Sulfidation: A 3% pyridine solution of xanthan hydride was used as a sulfiding agent to perform sulfidation, followed by washing with acetonitrile.

[0248] (4) Hydroxyl group protection A 10% anhydrous tetrahydrofuran acetate solution (CAP A) and tetrahydrofuran / pyridine / methylimidazole 74 / 10 / 16 (v / v / v) (CAP B) were used as hydroxyl group protection reagents, and then the samples were washed with acetonitrile.

[0249] The above operations were repeated, and the steps were cycled through according to the set nucleotide sequence order to obtain a sense strand product or antisense strand product having a specific sequence configuration.

[0250] (5) A 3% toluene dichloroacetate solution was used as a deprotection agent to remove the DMT protecting group of the last nucleotide, followed by washing with acetonitrile.

[0251] (6) Ammonia decomposition and purification The solid support, after the reaction was complete, was transferred to a reactor, concentrated aqueous ammonia (25%-28% by mass) was added, and ammonia decomposition was maintained at 60°C for 12 hours. After that, the system was cooled to room temperature, the mixture was transferred to a pressure filtration tank and filtered, the filtration cake was rinsed with a mixed solution of purified water and ethanol, the filtrates were combined, passed through a chromatography column, concentrated, and freeze-dried to obtain 2'-OMe and 2'-F modified single-chain products.

[0252] (7) Discontinuation of TBDMS DMSO and triethylamine hydrofluoride were added to the obtained product, and the reaction was carried out at 60°C for 2 hours. Then, aqueous ammonium acetate solution was added to the reaction mixture, and it was shaken to mix homogeneously. Anhydrous ethanol was added, and it was shaken to mix homogeneously, after which crystallization was carried out at -20°C for 8 to 12 hours. After centrifugation, the supernatant was discarded, and the precipitate was rinsed with anhydrous ethanol to obtain an unmodified single-chain product.

[0253] (8) Annealing After purification, the sense and antisense strands were mixed in a 1:1 molar ratio, heated to 95°C, maintained for 3 minutes, and then slowly cooled to room temperature to form siRNA double strands.

[0254] The other sequences listed in Table 2 were synthesized using the method described above.

[0255] 2.2 Synthesis of template-modified siRNA modifiers of this disclosure For the siRNA modification in 2.2.2 of Example 1, the siRNA modification was synthesized by referring to 2.1 of Example 2. When synthesizing the base at the 5' end of the antisense chain (the last base), a monomer containing a phosphonic acid group at the 5' end, such as vinyl-(E)-phosphonate-A-OMe phosphoramidite monomer (formula 9) or vinyl-(E)-phosphonate-U-OMe phosphoramidite monomer (formula 10), was used, and an example of its structure is shown below. [ka]

[0256] For the DV39P template-modified sequence, synthesize the siRNA sequence by referring to 2.1 of Example 2. When synthesizing the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand, use the DNA monomer DMT-dA phosphoramidite monomer (Formula 11), DMT-dT phosphoramidite monomer (Formula 12), DMT-dC phosphoramidite monomer (Formula 13), or DMT-dG phosphoramidite monomer (Formula 14). For the DV40P template-modified product, when synthesizing the nucleotides at positions 2, 6, and 14 from the 5' end of the antisense strand and at position 16 from the 5' end of the sense strand, use one of the four monomers mentioned above. Illustrative structures of these monomers are as follows. [ka]

[0257] 2.3 Synthesis of Inverted siRNA Modifiers For the inverted siRNA modifiers, synthesize the siRNA modifiers by referring to 2.1 of Example 2. When synthesizing the terminal nucleotides of the sense strand or antisense strand, use the DNA monomers dA(Bz)-CE-Reverse(dAinV), dT(Bz)-CE-Reverse(dTinV), dC(Bz)-CE-Reverse(dCinV), or dG(Bz)-CE-Reverse(dGinV), and their structures are as follows. [ka]

[0258] 2.4 Synthesis of siRNA Conjugates For the conjugates in which a GalNAc conjugate group G101 (whose structural formula is shown below) is linked to the 3' end of the sense chain in Table 9, the method for linking the oligonucleotide with G101 should be referred to in Example 3 of Patent Application CN116854754A. [ka]

[0259] Here, the oligonucleotide and the conjugate group G101 formed the conjugate shown below. [ka]

[0260] The G101 in the sequence number indicates that the sequence is linked to the conjugate group G101. L10 is the conjugate group of the positive reference (siFXIg1-M1SP, which showed the highest activity in CN113227376B). L10 indicates that the sequence is linked to the conjugate group L10. The structural formula of L10 is as follows. [ka]

[0261] Example 3: In vitro experiment to demonstrate the inhibitory effect of siRNA on FXI gene expression 3.1. Repressive effect of motifs and fluorine-oxygen alternating siRNA modifiers on FXI gene expression The siRNA motif synthesized in Example 2 and the siRNA modifications alternating with 2'-OMe and 2'-F were introduced into HepG2 cells by lipid nanoparticle (LNP) transfection. The inhibitory effect of each siRNA on the target gene FXI was then measured using qPCR and ELISA.

[0262] 3.1.1. Measurement of FXI mRNA expression repression rate by qPCR HepG2 cell lines were cultured in 10% fetal bovine serum DMEM culture medium (supplemented with 100x penicillin and 100x streptomycin at 10 μL / mL) and placed in a cell incubator containing 5% CO2 at 37°C.

[0263] Before transfecting cells with siRNA, Lipofectamine RNAiMAX (Invitrogen, 13778150) and Opti-MEM were mixed in a 2:98 ratio, then vortexed to homogeneous mix and prepare the transfection mixture. The siRNA compound was diluted to the appropriate concentration with Opti-MEM. For transfection at a single concentration point, the prepared concentration of siRNA was 960 pM. 55 μL of Opti-MEM diluted siRNA solution was taken in a 1:1 (v / v) ratio and added to 55 μL of the transfection mixture.

[0264] For the blank control group, 55 μL of the prepared transfection mixture was added to 55 μL of Opti-MEM. The mixture was vortexed to mix uniformly and allowed to stand at room temperature for 15 minutes.

[0265] The prepared transfection reagent was added to a 24-well cell culture plate (100 μL per well) to achieve a final siRNA concentration of 80 pM per well. 500 μL of cell suspension (cell density 1.5 × 10⁶) was added. 5 (at a concentration of / mL) was added. After homogeneous mixing using the cross-mixing method, the cells were placed in a 37°C, 5% CO2 cell incubator and cultured for 48 hours.

[0266] After 48 hours of transfection, RNA extraction was first performed according to the instructions of the RNA extraction kit (RNeasy Mini Kit, QIAGEN, 74106), then the RNA was reverse transcribed into cDNA using the reverse transcription kit FastKing RT Kit (with gDNase) (TIANGEN, KR116-02), and finally TB Green® Premix Ex Taq. TM The FXI mRNA expression level was quantitatively measured by qPCR using the (Tli RNaseH Plus) kit (Takara, RR420W (L×5)). See Table 10 for the amplification primers used in the qPCR experiment. The qPCR reaction procedure was as follows: Heat at 95°C for 30 seconds, then enter cycle mode, heat at 95°C for 5 seconds, and then heat at 60°C for 34 seconds, for a total of 40 cycles.

[0267] [Table 15]

[0268] The formula for calculating the FXI mRNA expression rate (%) is as follows: Expression rate = (FXI mRNA expression level / Blank control group FXI mRNA expression level) × 100%; FXI gene expression suppression rate = 100% - expression rate (%). See Table 11 for results.

[0269] 3.1.2. Measurement of FXI protein expression repression rate by ELISA For siRNAs that showed high suppression rates as measured by qPCR, ELISA was performed on the supernatant of cell culture media transfected with the siRNA for 48 hours using the Human Factor XI ELISA Kit (Thermo Fisher, EH118RB) to measure their suppressive effect on the target gene FXI at the protein level.

[0270] The ELISA data was processed and normalized using the transfection reagent control group as the baseline (expression level relative to the transfection reagent control group = protein expression level of each sample FXI / protein expression level of the transfection reagent control group sample FXI). See Table 11 for the results.

[0271] [Table 16] TIFF2026182852000081.tif223170TIFF2026182852000082.tif178170

[0272] The repression rates in this example are the average values ​​of three experiments; see Table 11. According to the qPCR results, of the 106 siRNA modifiers using alternating 2'-OMe and 2'-F modifications, 49 showed repression rates exceeding 60% for FXI gene expression, 34 showed repression rates between 40% and 60%, and 23 showed repression rates below 40%. Of these, the positive reference APC-AL showed a repression rate of 59%. In the ELISA experiment, the positive reference APC-AL showed a repression rate of 46%, and of the 27 superior siRNAs measured, 25 showed higher repression rates than the positive reference.

[0273] 3.2. Repressive effect of template-modified siRNA modifiers on FXI gene expression The siRNA modifiers modified with the modification template of this disclosure synthesized in Example 2 (see Table 7 for sequences) were introduced into HepG2 cells by lipid nanoparticle (LNP) transfection, and the repression rate against the target gene FXI was measured using qPCR and ELISA.

[0274] The experimental steps were almost identical to those in 3.1, the only difference being that the siRNA transfection concentration was 10 pM. See Table 12 for the experimental results.

[0275] [Table 17] TIFF2026182852000084.tif226164TIFF2026182852000085.tif226164TIFF2026182852000086.tif38164

[0276] As can be seen from Table 12, the siRNA modifiers according to this disclosure showed excellent repressive effects on the FXI gene. Furthermore, compared to the Advanced ESC template DV22 disclosed in the prior art, the siRNA modifiers modified with the modification template of this disclosure have a stronger gene expression repressive effect.

[0277] 3.3. Repressive effect of inverted and off-target modified modifiers on FXI gene expression The siRNA-modified products (sequences are shown in Table 8) obtained by inversion modification and off-target prevention modification, synthesized in Example 2, were introduced into HepG2 cells by lipid nanoparticle (LNP) transfection. The transfection concentrations were 1.00E+02, 5.00E+01, 2.50E+01, 1.30E+01, 1.60E+00, 2.00E-01, 2.40E-02, 3.10E-03, 3.80E-04, 4.80E-05, and 6.00E-06 nM, respectively. The inhibitory effect on the target gene FXI was measured at each concentration point using qPCR technology, and IC50 was measured. 50 I calculated it.

[0278] I C 50 Based on the results of the maximum inhibition rate (transfection at the highest concentration point), IC50 of five siRNA modifiers, including C00211-DV25P, C00211-DV25PInV, C00211-DV25PInVs, C00211-DV25Pd7B, and C00211-DV25P6InV, was observed. 50 All values ​​are positive reference ICs for APC-SL. 50 We found that the value was smaller than the positive reference, meaning the drug's efficacy was superior to that of the positive reference.

[0279] Example 4: Suppressive effect of siRNA conjugate on FXI gene expression in humanized mice In this example, the inhibitory effect of the siRNA conjugates listed in Table 9 on in vivo FXI protein expression was measured by ELISA experiments using transgenic mice expressing the human-derived FXI gene. The positive reference drug was L10-siFXIg1-M1SP, the compound with the highest activity as shown in patent CN113227376B.

[0280] 4.1 Inhibitory effect of siRNA conjugates on mouse FXI protein expression Six- to eight-week-old hFXI transgenic male mice were introduced to the housing facility and subjected to an acclimatization period of approximately one week. They were then divided into groups of 6 mice each, totaling 40 groups, including a vehicle group (physiological saline), a negative control group, a positive control group, and a test substance group (Table 14). The dose was 1 mpk, administered as a single subcutaneous injection. Serum hFXI levels were measured using an ELISA kit on days 7, 14, 21, 28, 35, 42, and 49 post-administration, and the inhibitory rate of the drug on FXI protein expression in mice was calculated.

[0281] [Table 18] TIFF2026182852000088.tif229164TIFF2026182852000089.tif57164

[0282] As can be seen from Table 13, experimental results from administering high-dose siRNA conjugates to humanized mice showed that the inhibition rate of positive reference DPC-SL10 on day 28 was 61.12%, and the inhibition rates of 14 siRNA conjugates were higher than that of the positive reference, indicating that they could suppress in vivo FXI expression within 28 days. Of these, five candidate compounds included D00211-DV34PG101, D00211s-DV25SPG101, D00211-DV25PG101, D00211-DV34PInVG101, and D00216-DV34PG101, and their inhibition rates were 80% or higher. On day 49, the inhibition rate of the positive reference DPC-SL10 was reduced to 17.40%, and the inhibition rates of 13 siRNA conjugates were higher than those of the positive reference. Of these, four siRNA conjugates—D00211s-DV25SPG101 (70.09%), D00211-DV25PG101 (65.65%), D00211-DV34PG101 (58.22%), and D00216-DV34PG101 (53.33%)—showed higher inhibition rates than 50%, demonstrating high pharmacokinetic activity.

[0283] To further screen for highly active compounds, eight sequences (see Table 14) that showed excellent pharmacokinetic activity in high-dose mouse experiments were selected and subjected to low-dose experiments along with the positive reference DPC-SL10 and vehicle groups. The dose in the low-dose group experiments was 0.5 mpk, with 8 mice per group, for a total of 10 groups.

[0284] [Table 19]

[0285] As can be seen from Table 14, in experiments in which low-dose siRNA conjugates were administered to humanized mice, the lowest serum FXI suppression rate in each group appeared on day 7. Of these, seven siRNA conjugates (D00211-DV25PG101, D00211-DV25PInVG101, D00211-DV34PG101, D00211-DV34PInVsG101, D00211s-DV25SPG101, D00212-DV32PG101, D00216-DV34PG101) showed higher suppression rates than the positive reference DPC-SL10 (63.56%), demonstrating high pharmacokinetic activity. On day 49, serum FXI content in the positive reference group recovered to baseline (suppression rate of -1.01%), and the suppression rates for D00211s-DV25SPG101 (55.87%), D00211-DV34PG101 (44.06%), D00211-DV25PG101 (40.69%), D00216-DV34PG101 (23.58%), and D00212-DV32PG101 (22.11%) were significantly higher than those of the positive reference group, indicating higher pharmacokinetic activity.

[0286] 4.2 Prolongation effect of siRNA conjugates on APTT (Activated Partial Thromboplastin Time) in humanized mice For the eight siRNA conjugates and positive references in Table 15, APTT was measured at D49 in high-dose and low-dose experiments, and the results are shown in Table 15 below.

[0287] [Table 20]

[0288] According to Table 15, compared to the vehicle group, the APTT of all eight siRNA conjugates and the positive reference was prolonged in the high-dose group experiment, and the prolongation rates for D00211-DV34PG101, D00211s-DV25SPG101, and D00212-DV32PG101 were all greater than 50%. In the low-dose group experiment, the prolongation rates for D00211-DV25PG101, D00211-DV34PG101, and D00211s-DV25SPG101 were greater than 10%.

[0289] Example 5: Pharmacological effects of siRNA conjugates in cynomolgus monkeys In this example, the pharmacokinetic effects of siRNA in cynomolgus monkeys were evaluated by measuring serum FXI protein levels, liver FXI mRNA expression levels, serum FXI activity, and APTT (Activated Partial Thromboplastin Time). The positive reference DPC4059-SL10 is compound L10-siFXIf1-M1SP in patent CN113227376B.

[0290] Prior to administration, animals were divided into groups based on serum FXI protein content and body weight, and considering measurable indicators such as APTT and PT (Prothrombin Time), and FXI activity. Each group consisted of 3 male animals, for a total of 6 groups, including 5 siRNA conjugate groups and 1 positive reference group. Administration was performed by a single subcutaneous injection (cervical dorsal injection). The dose was designed at 1 mg / kg, and the administration volume was 1 mL / kg, so the administration concentration was set to 1 mg / mL. The day of administration was designated as D0, and the observation cycle was 84 days.

[0291] 5.1 Measurement of serum FXI content Using ELISA, serum FXI protein content was measured on D-1 before the test administration and on D7, 14, 21, 28, 42, 56, 70, and 84 after administration. The inhibition rate was calculated, and refer to Table 16.

[0292] [Table 21]

[0293] According to Table 16, the five siRNA conjugates and the positive reference DPC4059-SL10 showed an inhibitory effect on cynomolgus monkey serum FXI expression on day 7 after administration, with the maximum inhibition rate occurring on day 28. The inhibition rates of all five siRNA conjugates were higher than those of the positive reference. At the experimental endpoint on day 84, the inhibition rate in each group was higher than 60%.

[0294] 5.2 Measurement of hepatic FXI mRNA expression Liver biopsies were performed on cynomolgus monkeys before administration and on days 28, 56, and 84 after administration. Approximately 5 mg of tissue was collected each time, total RNA was extracted, and the FXI mRNA expression level was measured by RT-qPCR to calculate the suppression rate.

[0295] [Table 22]

[0296] According to the table above, on D56, the FXI mRNA levels in each group were reduced to the lowest levels, and among them, D00211-DV34PG101, D00216-DV34PG101, D00211-DV34PInVsG101 and D00211s-DV25SPG101 showed higher suppression rates against hepatic FXI mRNA than the positive control DPC4059-SL10. On D84, the suppression rates against hepatic FXI mRNA of all five siRNA conjugates were higher than those of the positive reference DPC4059-SL10.

[0297] 5.3 Measurement of serum FXI activity Coagulation time was measured using a semi-automated blood coagulation analyzer, and FXI activity in plasma was measured on D-1 before administration and D7, 14, 21, 28, 42, 63, 77, and 84 after administration. Specifically, whole blood was collected using a 3.8% sodium citrate anticoagulant blood collection tube, thoroughly mixed (to avoid hemolysis or coagulation), and immediately after whole blood collection, it was centrifuged at room temperature. The plasma was separated by centrifugation at 2500g at room temperature for 15 minutes, and the plasma was diluted 10-fold with Owren-Koller diluent. 50 μL of FXI-deficient plasma and 50 μL of the test plasma sample were mixed and incubated at 37°C for 1 minute. 50 μL of APTT reagent and one magnetic bead were added, and the mixture was incubated at 37°C for 3 minutes. Finally, CaCl2 solution was added, immediately mixed homogeneously at 37°C, and the coagulation time was measured. FXI activity and reduction rate were calculated based on the standard curve of FXI activity-coagulation time. Table 18 shows that five siRNA conjugates and the positive reference treatment group induced a reduction in FXI activity in cynomolgus monkeys on D7, and this reduction persisted until D84.

[0298] [Table 23]

[0299] 5.3 APTT and PT Measurement Using a fully automated blood coagulation analyzer, plasma APTT and PT measurements were performed before administration (D-1) and after administration (D7, 14, 21, 28, 42, 56, 70, and 84) to evaluate the effects of siRNA conjugates on intrinsic and extrinsic coagulation pathway function. Specifically, whole blood was collected using 3.8% sodium citrate anticoagulant blood collection tubes, thoroughly mixed (to avoid hemolysis or coagulation), and immediately transferred to the clinical laboratory under room temperature conditions. The blood was then centrifuged at 3500 rpm / min at room temperature for 15 minutes to separate the plasma. APTT and PT were immediately measured using the analyzer, and the APTT prolongation rate was calculated compared to pre-administration (D-1) for each animal group. The measurement results are shown in Tables 19-21 below.

[0300] [Table 24] [Table 25] [Table 26]

[0301] Tables 19 and 210 show that the five siRNA conjugates and the positive reference caused APTT prolongation in cynomolgus monkeys, with no apparent effect on PT, indicating that the drugs prolonged clotting time by modulating the intrinsic coagulation pathway while not affecting the extrinsic coagulation pathway. Table 21 shows that the five siRNA conjugates showed varying degrees of APTT prolongation on day 7. From day 7 to day 42, the APTT prolongation rates of all five siRNA conjugates were higher than those of the positive control DPC4059-SL10. On day 84, the APTT prolongation rates of D00211-DV34PG101 and D00216-DV34PG101 were 49.70% and 48.31%, respectively, demonstrating strong pharmacokinetic activity.

[0302] Example 6: Comparison of the sequence of this patent with the sequence disclosed in the prior art In this example, the unmodified sequences B00209, B00210, B00211, B00211s, B00212, B00215, B00216, and B00404 of this disclosure were compared with similar unmodified sequences disclosed in the prior art in terms of sequence structure and in vitro pharmacokinetic activity.

[0303] 6.1 Comparison of Sequence Structures The sequences disclosed in prior art are very similar to the sequences in this disclosure, and the table below shows information such as the sequence, length, position, and terminal variations.

[0304] [Table 27] TIFF2026182852000099.tif228163TIFF2026182852000100.tif227163TIFF2026182852000101.tif75163

[0305] 6.2 Comparison of In Vitro Therapeutic Activity At the in vitro cell level, the inhibitory effect of unmodified sequences disclosed in the prior art on the expression of the target gene FXI was compared with that of the unmodified sequences disclosed herein. The specific experimental method was almost the same as in 3.1.1, except that cell transfection experiments were performed in 96-well plates with 3000 cells / well, and the final siRNA transfection concentrations were 0.01 nM and 0.10 nM. After 48 hours, RNA was extracted, and the repression rate of FXI gene expression was measured using qPCR. See Table 23 for the results. The unmodified sequences in this disclosure showed significantly higher activity compared to similar unmodified sequences disclosed in the prior art.

[0306] [Table 28]

[0307] While specific embodiments of this disclosure have been described in detail, these examples and specific embodiments should not be considered limiting to this disclosure. Those skilled in the art will understand that various modifications and substitutions can be made to those details based on all the disclosed teachings without departing from the spirit and intent of this disclosure. Any such modifications will fall within the scope of protection of this disclosure. The entire scope of this disclosure is given by the appended claims and any equivalents thereof.

Claims

1. An siRNA double-stranded molecule, wherein the siRNA double-stranded molecule comprises a sense strand and an antisense strand that form a reverse complementary double-stranded region, and the antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotides complementary to a target sequence whose nucleotide sequence is TTTCAGGATGATTTTCTATATCAAGT or ACTTCAGTTTCTGGGTGAATGT.

2. The antisense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof in a sequence shown in any one of SEQ ID NO: 114-118, 121-123, and 139, and / or The siRNA double-stranded DNA according to claim 1, characterized in that the sense strand comprises at least 15, 16, 17, 18, or 19 consecutive nucleotide fragments or modified fragments thereof in a sequence shown in any one of SEQ ID NO: 8-12, 15-17, and 33.

3. The siRNA double strand comprises one or at least two combinations selected from the following oligonucleotide double strands consisting of a sense strand and an antisense strand pair, and optionally, the sense strand and the antisense strand each independently contain at least one modified nucleotide. (1) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 8, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

114. (2) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 9, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

115. (3) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 10, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

116. (4) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 11, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

117. (5) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 12, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

118. (6) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 15, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

121. (7) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 16, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

122. (8) The sense strand has the sequence or fragment thereof shown in SEQ ID NO: 17, and the antisense strand has the sequence or fragment thereof shown in SEQ ID NO:

123. (9) The siRNA double strand according to claim 2, characterized in that the sense strand has the sequence shown in SEQ ID NO: 33 or a fragment thereof, and the antisense strand has the sequence shown in SEQ ID NO: 139 or a fragment thereof.

4. The nucleotide sequence of the sense strand has a difference of 1 to 3 nucleotides from any one of the sequences among SEQ ID NO: 8 to 12, 15 to 17, and 33, and / or The siRNA double-stranded device according to any one of claims 1 to 3, characterized in that the nucleotide sequence of the antisense strand has a difference of 1 to 3 nucleotides from any one of the sequences among SEQ ID NO: 114-118, 121-123, and 139.

5. The siRNA double strand according to any one of claims 1 to 3, characterized in that the sense strand or antisense strand comprises at least one modified nucleotide, the modified nucleotide being selected from deoxy-nucleotides, 3'-terminal deoxythymine nucleotides, 2'-O-methyl-modified nucleotides, 2'-fluoro-modified nucleotides, 2'-deoxy-modified nucleotides, lock nucleotides, unlock nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, non-basic nucleotides, 2'-amino-modified nucleotides, 2'-O-allyl-modified f-nucleotides, 2'-C-alkyl-modified nucleotides, 2'-hydroxy-modified nucleotides, 2'-methoxyethyl-modified nucleotides, 2'-O-alkyl-modified nucleotides, morpholinyl nucleotides, phosphoramides, nucleotides containing unnatural bases, tetrahydropyran-modified nucleotides, 1,5-anhydrohexitol-modified nucleotides, cyclohexenyl-modified nucleotides, nucleotides containing phosphorothioate groups, nucleotides containing methyl phosphate groups, nucleotides containing 5'-phosphate groups, and nucleotides containing 5'-phosphate mimetic groups, and combinations thereof.

6. The siRNA double-stranded molecule according to any one of claims 1 to 3, characterized in that at least one strand contains the 3' overhang of at least one or at least two nucleotides.

7. The siRNA double-stranded molecule according to any one of claims 1 to 3, characterized in that the sense strand has 21 nucleotides and the antisense strand has 23 nucleotides, or the sense strand has 20 nucleotides and the antisense strand has 22 nucleotides.

8. The siRNA double-stranded molecule according to any one of claims 1 to 3, characterized in that all nucleotide modification forms in the sense strand and antisense strand are chemical modifications at the 2' position of nucleotide ribose, wherein the chemical modification at the 2' position of nucleotide ribose is one or a combination of any one of 2'-methoxy, 2'-methoxyethyl, 2'-fluoro, 2'-deoxy, 2'-benzyloxy, 2'-methylcarbonylamino, and 2'-pyridylmethoxy.

9. The siRNA double-stranded molecule according to claim 8, characterized in that the chemical modification at the 2' position of each nucleotide ribose is selected from an alternating combination of 2'-methoxy and 2'-fluoro.

10. The chemical modification configuration of the 2' position of each nucleotide ribose is such that all odd positions on the antisense strand are 2'-methoxy modified, all even positions are 2'-fluoro modified, and on the sense strand, the position opposite the 2'-methoxy modification on the antisense strand is 2'-fluoro modified, the position opposite the 2'-fluoro modification is 2'-methoxy modified, and / or The siRNA double-stranded device according to claim 8, characterized in that one, two, or three 3',5'-phosphorothioate bonds may be present between the nucleotides from the 5' end to positions 1 through 4 of the sense strand and / or the antisense strand, and one, two, or three 3',5'-phosphorothioate bonds may be present between the nucleotides from the 3' end to positions 1 through 4 of the antisense strand.

11. Regarding the phosphorylation of the 5' carbon atom of the 5'-terminal nucleotide glycoside of the modified antisense chain, the phosphorylation of the 5' carbon atom is selected from the following 5' phosphorylation groups: 5'-vinylphosphonate group, 5'-methylphosphonate group, 5'-C-methylphosphate group, 5'-phosphorothioate group, and 5'-phosphate group, and their structures are as follows: 【Chemistry 1】 Here, R is hydrogen, hydroxyl group, amino group, C 1-4 Alkyl group, aromatic group, C 1-4 Alkoxy group, C 1-4 It is an alkylcarbonylamino group or a halogen, The siRNA double-stranded molecule according to claim 3, characterized in that the base is selected from adenine, guanine, cytosine, thymine, and uracil.

12. The antisense chain and the sense chain are modified in the following modification forms: (1) The antisense chain has one of the following modification forms A to H: Table 1 and / or, the sense chain may use one of the following modification forms a to c: Table 2 Here, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro, 2'-Deoxy represents 2'-deoxy, PS represents a linkage starting from the 5' end and between the nucleotide at that position and the adjacent nucleotide to its right via a phosphorothioate bond, and EVP represents 5'-vinyl-(E)-phosphonate. Preferably, the antisense chain is modified in modification form A, and the sense chain is modified in modification form a, or The antisense chain is modified with modification form B, and the sense chain is modified with modification form a, or The antisense chain is modified with modification form C, and the sense chain is modified with modification form a, or The antisense chain is modified with modification form C, and the sense chain is modified with modification form b, or The antisense chain is modified with modification form D, and the sense chain is modified with modification form b, or The antisense chain is modified with modification form E, and the sense chain is modified with modification form b, or The antisense chain is modified with modification form F, and the sense chain is modified with modification form b, or The antisense chain is modified with modification form G, and the sense chain is modified with modification form b, or The antisense chain is modified with modification form H, and the sense chain is modified with modification form c. (2) The antisense chain has one of the following modification forms A' to G': Table 3 and / or, the sense chain may use the following modification form a' or b': Table 4 Herein, 2'-OMe represents 2'-methoxy, 2'-F represents 2'-fluoro; 2'-Deoxy represents 2'-deoxy; PS represents a linkage between the nucleotide at the 5' end and the adjacent nucleotide to its right by a phosphorothioate bond; and EVP represents 5'-vinyl-(E)-phosphonate, characterized in that the siRNA double-stranded molecule according to any one of claims 1 to 3.

13. The antisense chain is modified in modification form A', and the sense chain is modified in modification form a', or The antisense chain is modified in modification form B', and the sense chain is modified in modification form a', or The antisense chain is modified in modification form C', and the sense chain is modified in modification form a', or The antisense chain is modified in modification form C', and the sense chain is modified in modification form b', or The antisense chain is modified in modification form D', and the sense chain is modified in modification form b', or The antisense chain is modified in modification form E', and the sense chain is modified in modification form b', or The antisense chain is modified in modification form F', and the sense chain is modified in modification form b', or The siRNA double strand according to claim 12, characterized in that the antisense strand is modified with modification form G', and the sense strand is modified with modification form b'.

14. The siRNA double strand comprises one or at least two combinations selected from the following oligonucleotide double strands consisting of a sense strand pair and an antisense strand pair: (1) The sense strand has the sequence shown in SEQ ID NO: 220, and the antisense strand has the sequence shown in SEQ ID NO:

326. (2) The sense strand has the sequence shown in SEQ ID NO: 221, and the antisense strand has the sequence shown in SEQ ID NO:

327. (3) The sense strand has the sequence shown in SEQ ID NO: 222, and the antisense strand has the sequence shown in SEQ ID NO:

328. (4) The sense strand has the sequence shown in SEQ ID NO: 223, and the antisense strand has the sequence shown in SEQ ID NO:

329. (5) The sense strand has the sequence shown in SEQ ID NO: 224, and the antisense strand has the sequence shown in SEQ ID NO:

330. (6) The sense strand has the sequence shown in SEQ ID NO: 227, and the antisense strand has the sequence shown in SEQ ID NO:

333. (7) The sense strand has the sequence shown in SEQ ID NO: 228, and the antisense strand has the sequence shown in SEQ ID NO:

334. (8) The sense strand has the sequence shown in SEQ ID NO: 229, and the antisense strand has the sequence shown in SEQ ID NO:

335. (9) The sense strand has the sequence shown in SEQ ID NO: 245, and the antisense strand has the sequence shown in SEQ ID NO:

351. (10) The sense strand has the sequence shown in SEQ ID NO: 426, and the antisense strand has the sequence shown in SEQ ID NO:

552. (11) The sense strand has the sequence shown in SEQ ID NO: 427, and the antisense strand has the sequence shown in SEQ ID NO:

553. (12) The sense strand has the sequence shown in SEQ ID NO: 429, and the antisense strand has the sequence shown in SEQ ID NO:

555. (13) The sense strand has the sequence shown in SEQ ID NO: 430, and the antisense strand has the sequence shown in SEQ ID NO:

556. (14) The sense strand has the sequence shown in SEQ ID NO: 431, and the antisense strand has the sequence shown in SEQ ID NO:

557. (15) The sense strand has the sequence shown in SEQ ID NO: 435, and the antisense strand has the sequence shown in SEQ ID NO:

561. (16) The sense strand has the sequence shown in SEQ ID NO: 439, and the antisense strand has the sequence shown in SEQ ID NO:

565. (17) The sense strand has the sequence shown in SEQ ID NO: 440, and the antisense strand has the sequence shown in SEQ ID NO:

566. (18) The sense strand has the sequence shown in SEQ ID NO: 442, and the antisense strand has the sequence shown in SEQ ID NO:

568. (19) The sense strand has the sequence shown in SEQ ID NO: 443, and the antisense strand has the sequence shown in SEQ ID NO:

569. (20) The sense strand has the sequence shown in SEQ ID NO: 444, and the antisense strand has the sequence shown in SEQ ID NO:

570. (21) The sense strand has the sequence shown in SEQ ID NO: 445, and the antisense strand has the sequence shown in SEQ ID NO:

571. (22) The sense strand has the sequence shown in SEQ ID NO: 446, and the antisense strand has the sequence shown in SEQ ID NO:

572. (23) The sense strand has the sequence shown in SEQ ID NO: 447, and the antisense strand has the sequence shown in SEQ ID NO:

573. (24) The sense strand has the sequence shown in SEQ ID NO: 448, and the antisense strand has the sequence shown in SEQ ID NO:

574. (25) The sense strand has the sequence shown in SEQ ID NO: 449, and the antisense strand has the sequence shown in SEQ ID NO:

575. (26) The sense strand has the sequence shown in SEQ ID NO: 450, and the antisense strand has the sequence shown in SEQ ID NO:

576. (27) The sense strand has the sequence shown in SEQ ID NO: 454, and the antisense strand has the sequence shown in SEQ ID NO:

580. (28) The sense strand has the sequence shown in SEQ ID NO: 455, and the antisense strand has the sequence shown in SEQ ID NO:

581. (29) The sense strand has the sequence shown in SEQ ID NO: 456, and the antisense strand has the sequence shown in SEQ ID NO:

582. (30) The sense strand has the sequence shown in SEQ ID NO: 468, and the antisense strand has the sequence shown in SEQ ID NO:

594. (31) The sense strand has the sequence shown in SEQ ID NO: 471, and the antisense strand has the sequence shown in SEQ ID NO:

597. (32) The sense strand has the sequence shown in SEQ ID NO: 477, and the antisense strand has the sequence shown in SEQ ID NO:

603. (33) The sense strand has the sequence shown in SEQ ID NO: 478, and the antisense strand has the sequence shown in SEQ ID NO:

604. (34) The sense strand has the sequence shown in SEQ ID NO: 479, and the antisense strand has the sequence shown in SEQ ID NO:

605. (35) The sense strand has the sequence shown in SEQ ID NO: 480, and the antisense strand has the sequence shown in SEQ ID NO:

606. (36) The sense strand has the sequence shown in SEQ ID NO: 529, and the antisense strand has the sequence shown in SEQ ID NO:

655. (37) The sense strand has the sequence shown in SEQ ID NO: 530, and the antisense strand has the sequence shown in SEQ ID NO:

656. (38) The siRNA double strand according to claim 1, characterized in that the sense strand has the sequence shown in SEQ ID NO: 532 and the antisense strand has the sequence shown in SEQ ID NO:

658.

15. The nucleotides from the 5' end of the antisense strand, from position 2 to position 8, are each independently modified nucleotides, and these modified nucleotides are either unlocked nucleic acid or ethylene glycol nucleic acid, or the nucleotides from the 5' end of the antisense strand, from position 2 to position 8, are each independently DNA, where the structures of unlocked nucleic acid and ethylene glycol nucleic acid are as follows: 【Chemistry 2】 Here, the base is one selected from adenine, guanine, cytosine, thymine, and uracil, and / or The 3' end of the sense strand or the antisense strand is an inverted modified nucleotide, or the 6th or 7th position of the 5' end of the sense strand is an inverted modified nucleotide, where the modified nucleotide is 【Transformation 3】 The siRNA double strand according to claim 3 or 14, characterized in that it is selected from dAinV, dTinV, dGinV, and dCinV having the following structure.

16. The siRNA double strand comprises one or at least two combinations selected from the following oligonucleotide double strands consisting of a sense strand pair and an antisense strand pair: (1) The sense strand has the sequence shown in SEQ ID NO: 677, and the antisense strand has the sequence shown in SEQ ID NO:

686. (2) The sense strand has the sequence shown in SEQ ID NO: 678, and the antisense strand has the sequence shown in SEQ ID NO:

687. (3) The sense strand has the sequence shown in SEQ ID NO: 683, and the antisense strand has the sequence shown in SEQ ID NO:

693. (4) The siRNA double strand according to claim 15, characterized in that the sense strand has the sequence shown in SEQ ID NO: 680 and the antisense strand has the sequence shown in SEQ ID NO:

689.

17. A conjugate for reducing FXI expression, wherein the conjugate comprises a double strand of siRNA as described in any one of claims 1 to 16 and a conjugate group linked thereto.

18. The conjugate group is ligated to the 3'-terminus or 5'-terminus of the oligonucleotide sense chain, and / or The conjugate according to claim 17, characterized in that the conjugate group is a GalNAc derivative added using a divalent or trivalent branched linker arm.

19. The conjugate group is one selected from the following conjugate groups: (1) The conjugate group is 【Chemistry 4】 And, Here, X is a hydroxyl protecting group or H, the hydroxyl protecting group is selected from an acetyl group, a benzoyl group, or an isobutyryl group; Y is an amine protecting group or H, the amine protecting group is selected from a formyl group, an acetyl group, a propionyl group, an n-butyryl group, or an isobutyryl group; n is an integer from 0 to 20; and q, r, and s are independently integers from 1 to 7. (2) The conjugate group is 【Transformation 5】 Here, X is oxygen, -N(Y)-, or sulfur. Y is C 1-4 Alkyl alkyl group or C 6-10 It is an aryl group, R 1 It is oxygen or sulfur, R 2 is hydrogen, -NH 2 , C 1-4 alkyl group, C 6-10 aryl group, C 1-4 alkoxy group or halogen, A is - (CH 2 ) a -, - (CH 2 CH 2 O) b -, -((CH 2 ) c NHKCO) d - or - ((CH 2 ) c CONH) d - where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5. B is - (CH 2 ) e - and here e is an integer from 0 to 7, L is -CONH- or -NHCO-, X 1 is, -(CH 2 ) f - or - (CH 2 CH 2 O) f CH 2 - and f is an integer from 1 to 5, X 2 is, -(CH 2 ) g - and g is an integer from 1 to 6, X 3 It is oxygen or sulfur, Y 1 is 0 or 1, Y 2 is 0, 1, or 2, Y 3 If X is 1, 4 CH 2 Y 3 If X is 2, 4 CH is Y 3 If X is 3, 3 It is carbon, m is an integer between 0 and 4. n is an integer between 0 and 4. (3) The conjugate group is 【Transformation 6】 Here, X is oxygen, -N(Y)-, or sulfur. Y is C 1-4 Alkyl alkyl group or C 6-10 It is an aryl group, R 1 It is oxygen or sulfur, R 2 is hydrogen, -NH 2 , C 1-4 alkyl group, C 6-10 Aryl group, C 1-4 It is an alkoxy group or halogen, A is - (CH 2 ) a -, - (CH 2 CH 2 O) b -, -((CH 2 ) c NHKCO) d - or - ((CH 2 ) c CONH) d - where a is an integer from 1 to 15, b is an integer from 1 to 7, c is an integer from 1 to 7, and d is an integer from 1 to 5. B is - (CH 2 ) e - and here e is an integer from 0 to 7, L is -CONH- or -NHCO-, X 1 is, -(CH 2 ) f - or - (CH 2 CH 2 O) f CH 2 - and f is an integer from 1 to 5, X 2 is, -(CH 2 ) g - and g is an integer from 1 to 6, X 3 It is oxygen or sulfur, Y 1 is 0 or 1, Y 2 is 0, 1, or 2, Y 3 If X is 1, 4 CH 2 Y 3 If X is 2, 4 CH is Y 3 If X is 3, 3 It is carbon, m is an integer between 0 and 4. n is an integer between 0 and 4. The conjugate according to claim 17, wherein q is an integer from 0 to 4.

20. The aforementioned conjugate group is 【Transformation 7】 【change】 【change】 The conjugate according to feature 19.

21. The siRNA double strand comprises one or at least two combinations selected from the following oligonucleotide double strands consisting of a sense strand pair and an antisense strand pair: (1) The sense strand has the sequence shown in SEQ ID NO: 426, and the antisense strand has the sequence shown in SEQ ID NO:

552. (2) The sense strand has the sequence shown in SEQ ID NO: 427, and the antisense strand has the sequence shown in SEQ ID NO:

553. (3) The sense strand has the sequence shown in SEQ ID NO: 429, and the antisense strand has the sequence shown in SEQ ID NO:

555. (4) The sense strand has the sequence shown in SEQ ID NO: 430, and the antisense strand has the sequence shown in SEQ ID NO:

556. (5) The sense strand has the sequence shown in SEQ ID NO: 431, and the antisense strand has the sequence shown in SEQ ID NO:

557. (6) The sense strand has the sequence shown in SEQ ID NO: 435, and the antisense strand has the sequence shown in SEQ ID NO:

561. (7) The sense strand has the sequence shown in SEQ ID NO: 439, and the antisense strand has the sequence shown in SEQ ID NO:

565. (8) The sense strand has the sequence shown in SEQ ID NO: 440, and the antisense strand has the sequence shown in SEQ ID NO:

566. (9) The sense strand has the sequence shown in SEQ ID NO: 442, and the antisense strand has the sequence shown in SEQ ID NO:

568. (10) The sense strand has the sequence shown in SEQ ID NO: 443, and the antisense strand has the sequence shown in SEQ ID NO:

569. (11) The sense strand has the sequence shown in SEQ ID NO: 444, and the antisense strand has the sequence shown in SEQ ID NO:

570. (12) The sense strand has the sequence shown in SEQ ID NO: 445, and the antisense strand has the sequence shown in SEQ ID NO:

571. (13) The sense strand has the sequence shown in SEQ ID NO: 446, and the antisense strand has the sequence shown in SEQ ID NO:

572. (14) The sense strand has the sequence shown in SEQ ID NO: 447, and the antisense strand has the sequence shown in SEQ ID NO:

573. (15) The sense strand has the sequence shown in SEQ ID NO: 448, and the antisense strand has the sequence shown in SEQ ID NO:

574. (16) The sense strand has the sequence shown in SEQ ID NO: 449, and the antisense strand has the sequence shown in SEQ ID NO:

575. (17) The sense strand has the sequence shown in SEQ ID NO: 450, and the antisense strand has the sequence shown in SEQ ID NO:

576. (18) The sense strand has the sequence shown in SEQ ID NO: 454, and the antisense strand has the sequence shown in SEQ ID NO:

580. (19) The sense strand has the sequence shown in SEQ ID NO: 455, and the antisense strand has the sequence shown in SEQ ID NO:

581. (20) The sense strand has the sequence shown in SEQ ID NO: 456, and the antisense strand has the sequence shown in SEQ ID NO:

582. (21) The sense strand has the sequence shown in SEQ ID NO: 468, and the antisense strand has the sequence shown in SEQ ID NO:

594. (22) The sense strand has the sequence shown in SEQ ID NO: 471, and the antisense strand has the sequence shown in SEQ ID NO:

597. (23) The sense strand has the sequence shown in SEQ ID NO: 477, and the antisense strand has the sequence shown in SEQ ID NO:

603. (24) The sense strand has the sequence shown in SEQ ID NO: 478, and the antisense strand has the sequence shown in SEQ ID NO:

604. (25) The sense strand has the sequence shown in SEQ ID NO: 479, and the antisense strand has the sequence shown in SEQ ID NO:

605. (26) The sense strand has the sequence shown in SEQ ID NO: 480, and the antisense strand has the sequence shown in SEQ ID NO:

606. (27) The sense strand has the sequence shown in SEQ ID NO: 529, and the antisense strand has the sequence shown in SEQ ID NO:

655. (28) The sense strand has the sequence shown in SEQ ID NO: 530, and the antisense strand has the sequence shown in SEQ ID NO:

656. (29) The conjugate according to any one of claims 17 to 20, characterized in that the sense strand has the sequence shown in SEQ ID NO: 532 and the antisense strand has the sequence shown in SEQ ID NO:

658.

22. The aforementioned conjugate comprises one or at least two combinations selected from the following oligonucleotide double hedges consisting of a sense strand paired with an antisense strand: (1) The sense strand has the sequence shown in SEQ ID NO: 695, and the antisense strand has the sequence shown in SEQ ID NO:

732. (2) The sense strand has the sequence shown in SEQ ID NO: 706, and the antisense strand has the sequence shown in SEQ ID NO:

743. (3) The sense strand has the sequence shown in SEQ ID NO: 707, and the antisense strand has the sequence shown in SEQ ID NO:

744. (4) The sense strand has the sequence shown in SEQ ID NO: 708, and the antisense strand has the sequence shown in SEQ ID NO:

745. (5) The sense strand has the sequence shown in SEQ ID NO: 710, and the antisense strand has the sequence shown in SEQ ID NO:

747. (6) The sense strand has the sequence shown in SEQ ID NO: 713, and the antisense strand has the sequence shown in SEQ ID NO:

750. (7) The sense strand has the sequence shown in SEQ ID NO: 714, and the antisense strand has the sequence shown in SEQ ID NO:

751. (8) The sense strand has the sequence shown in SEQ ID NO: 715, and the antisense strand has the sequence shown in SEQ ID NO:

752. (9) The sense strand has the sequence shown in SEQ ID NO: 719, and the antisense strand has the sequence shown in SEQ ID NO:

756. (10) The sense strand has the sequence shown in SEQ ID NO: 720, and the antisense strand has the sequence shown in SEQ ID NO:

757. (11) The sense strand has the sequence shown in SEQ ID NO: 721, and the antisense strand has the sequence shown in SEQ ID NO:

758. (12) The sense strand has the sequence shown in SEQ ID NO: 722, and the antisense strand has the sequence shown in SEQ ID NO:

759. (13) The sense strand has the sequence shown in SEQ ID NO: 723, and the antisense strand has the sequence shown in SEQ ID NO:

760. (14) The sense strand has the sequence shown in SEQ ID NO: 724, and the antisense strand has the sequence shown in SEQ ID NO:

761. (15) The sense strand has the sequence shown in SEQ ID NO: 725, and the antisense strand has the sequence shown in SEQ ID NO:

762. (16) The sense strand has the sequence shown in SEQ ID NO: 728, and the antisense strand has the sequence shown in SEQ ID NO:

765. (17) The conjugate according to any one of claims 17 to 20, characterized in that the sense strand has the sequence shown in SEQ ID NO: 729 and the antisense strand has the sequence shown in SEQ ID NO:

766.

23. A nucleic acid protein composition comprising a double-stranded region of an siRNA double-stranded region as described in any one of claims 1 to 16, and a nuclease, Alternatively, the nucleic acid protein composition is characterized by comprising an antisense strand of the double-stranded region of the siRNA double-stranded region described in any one of claims 1 to 16, and a nuclease.

24. A pharmaceutical composition comprising a double-stranded siRNA according to any one of claims 1 to 16, a conjugate according to any one of claims 17 to 22, or a nucleic acid protein composition according to claim 23, and a pharmaceutically acceptable carrier.

25. Use of a double-stranded siRNA according to any one of claims 1 to 16, a conjugate according to any one of claims 17 to 22, a nucleic acid protein composition according to claim 23, or a pharmaceutical composition according to claim 24 in the manufacture of a drug for treating a disease related to FXI gene expression.

26. Use of a double-stranded siRNA according to any one of claims 1 to 16, a conjugate according to any one of claims 17 to 22, a nucleic acid protein composition according to claim 23, or a pharmaceutical composition according to claim 24 in the manufacture of an anticoagulant.